<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Creutzfeldt-Jakob disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Creutzfeldt-Jakob disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Creutzfeldt-Jakob disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brian S Appleby, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark L Cohen, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven T DeKosky, MD, FAAN, FACP, FANA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Glenn A Tung, MD, FACR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 24, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2233264067"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Prion diseases are neurodegenerative diseases that have long incubation periods and progress inexorably to death once clinical symptoms appear. Three categories of human prion diseases are recognized: </p><p class="bulletIndent1"><span class="glyph">●</span>Sporadic – Sporadic Creutzfeldt-Jakob disease (sCJD), sporadic fatal insomnia, and variably protease-sensitive prionopathy </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic – Genetic Creutzfeldt-Jakob disease (gCJD), fatal familial insomnia (FFI), and Gerstmann-Sträussler-Scheinker syndrome (GSS)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acquired – Kuru, iatrogenic Creutzfeldt-Jakob disease (iCJD), and variant Creutzfeldt-Jakob disease (vCJD) </p><p></p><p>sCJD is the most well-known and accounts for more than 90 percent of sporadic prion disease [<a href="#rid1">1</a>].</p><p>Human prion diseases share neuropathologic features including neuronal loss, proliferation of glial cells, absence of an inflammatory response, small vacuoles within the neuropil that produce a spongiform appearance, and the presence of protease-resistant prion protein.</p><p>The clinical manifestations and diagnosis of sCJD will be reviewed here. vCJD, kuru, GSS, FFI, the biology of prions, and the genetics of prion diseases are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5076.html" rel="external">"Variant Creutzfeldt-Jakob disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5074.html" rel="external">"Diseases of the central nervous system caused by prions"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>CJD is the most common of the human prion diseases, although it is still rare. Sporadic (sCJD), genetic (gCJD), iatrogenic (iCJD), and variant (vCJD) are all recognized. The vast majority of CJD cases are sporadic (85 to 95 percent), while 5 to 15 percent are due to gCJD; iCJD and vCJD generally account for less than 1 percent [<a href="#rid2">2,3</a>]. Approximately one to two new cases of sCJD occur per 1,000,000 individuals across the entire population per year with a worldwide distribution [<a href="#rid4">4</a>]. </p><p>The mean age for the onset of disease is approximately 62 years, although cases in young adults and those over 80 years of age have been described [<a href="#rid3">3,5-8</a>]. Patients with vCJD and iCJD tend to be much younger, which led to an early appreciation that the mode of transmission might be different. gCJD patients have only a slightly younger mean age of onset compared with sCJD [<a href="#rid9">9</a>].</p><p>There is no sex predilection for CJD.</p><p>In the United States, the incidence of CJD appears to be lower in African Americans and Native Americans including Alaska Natives compared with the White population; however, this observation may reflect ascertainment bias [<a href="#rid10">10,11</a>]. The incidence of CJD is increased 30- to 100-fold in certain geographic regions (including areas of North Africa, Israel, Italy, and Slovakia) due primarily to clusters of gCJD [<a href="#rid9">9</a>]. The intensity of national surveillance methods also influences the reported incidence of CJD, as well as other prion diseases [<a href="#rid4">4</a>]. </p><p>Epidemiologic studies have found conflicting associations between sCJD and a history of surgical procedures that do not include procedures recognized to cause iCJD [<a href="#rid12">12-15</a>]. The details of these studies vary with regard to the type of surgery, receipt of blood products, number of surgeries, and latency between surgery and the infection. In general, these are low-quality, small studies that may be influenced by recall bias. </p><p>Other risk factors that have been variably identified for CJD include residence on a farm [<a href="#rid12">12</a>], a family history of CJD (adjusted odds ratio [OR] 19.1), and medical history of psychosis (OR 9.9) [<a href="#rid16">16</a>]. </p><p>Although not pathogenic, genetic polymorphisms affect sCJD risk. The largest genetic risk factor for sCJD is the prion protein (<em>PRNP</em>) gene, particularly codons 129 and 219, which confer protection when heterozygous and increase risk when homozygous [<a href="#rid17">17</a>]. Single nucleotide polymorphisms outside of <em>PRNP</em>, including syntaxin 6 (<em>STX6</em>) and galactose-3-O-sulfotransferase 1 (<em>GAL3ST1</em>), may also increase risk of sCJD to a lesser degree [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H2007012547"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H2445028684"><span class="h2">Sporadic CJD</span><span class="headingEndMark"> — </span>Prions are infectious, protein-containing particles (PrP<sup>Sc</sup>) that replicate by auto-catalytic templating, replacing normal prion proteins (PrP<sup>C</sup>) and leading to neurotoxicity. This process is described separately. (See  <a class="medical medical_review" href="/z/d/html/5074.html" rel="external">"Diseases of the central nervous system caused by prions", section on 'Pathogenesis of prion diseases'</a>.)</p><p>In sporadic CJD (sCJD), the origins of the disease-causing form of the prion protein are not known, but are not thought to be acquired. Small clusters of sCJD cases have been reported [<a href="#rid19">19-21</a>]. A retrospective case-control study of all sCJD cases from 1990 to 1998 in the United Kingdom concluded that sCJD cases lived closer together than might be expected in the absence of a disease-clustering mechanism; the results suggested that some sCJD cases may result from exposure to a common external factor [<a href="#rid22">22</a>]. However, the significance of these possible clusters remains unclear. The results of one statistical analysis suggest that these apparent clusters may result from higher intensity of surveillance in localized geographic regions [<a href="#rid23">23</a>].</p><p>In addition to the prion strain reported to cause variant CJD (vCJD), other prion strains have been reported to cause spongiform encephalopathy in cattle [<a href="#rid24">24-26</a>]. One of these strains is associated with atypical amyloid deposition, a neuropathological feature not found in typical bovine spongiform encephalopathy (BSE) [<a href="#rid26">26</a>]. The pathologic prion protein (PrP<sup>Sc</sup>) molecular signature of this amyloidotic form of BSE (called BASE) is similar to that of sCJD subtype MV2 (see <a class="local">'Subtypes of sCJD'</a> below). The significance of this PrP<sup>Sc</sup> molecular similarity is unclear. One explanation is that some cases of sCJD with the PrP<sup>Sc</sup> MV2 pattern might be the result of exposure to BASE. However, it is important to recognize that glycosylation and migration patterns of PrP<sup>Sc</sup> may not be a reliable indicator of prion protein origin. Until further evidence accumulates, the role, if any, of BASE exposure as a source of sCJD is considered speculative [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H550499634"><span class="h2">Variant CJD</span><span class="headingEndMark"> — </span>Variant CJD is a distinct, acquired prion disease. Available evidence suggests that a single bovine prion strain responsible for BSE has infected humans to cause vCJD.</p><p>vCJD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5076.html" rel="external">"Variant Creutzfeldt-Jakob disease"</a>.)</p><p class="headingAnchor" id="H1590505628"><span class="h2">Genetic CJD</span><span class="headingEndMark"> — </span>Mutations of the gene encoding prion protein have been identified and associated with forms of genetic CJD (gCJD). gCJD contributes to less than 15 percent of CJD cases. </p><p>gCJD is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/5074.html" rel="external">"Diseases of the central nervous system caused by prions", section on 'Genetic CJD'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Iatrogenic CJD</span><span class="headingEndMark"> — </span>Iatrogenic CJD (iCJD) is believed to have been largely eradicated by current practices; new cases are likely to be those with very long incubation periods [<a href="#rid28">28</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Implicated procedures and incubation periods</strong> – Past cases of iCJD have followed administration of cadaveric human pituitary hormones (growth hormone and gonadotrophin) [<a href="#rid29">29-31</a>], dural graft transplants [<a href="#rid32">32-35</a>], use of dural mater [<a href="#rid36">36</a>], corneal transplants [<a href="#rid37">37,38</a>], use of contaminated neurosurgical instruments or stereotactic depth electrodes [<a href="#rid39">39</a>], and secondary infection with vCJD through transfusion of infected blood products. Dural graft transplants and use of cadaveric pituitary hormones account for the vast majority of iCJD cases [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1">The incubation period for iCJD is variable and depends upon the mode of transmission [<a href="#rid40">40</a>]. Studies have reported or estimated a mean time of 9 to 10 years for iCJD acquired after administration of human growth hormone and dural graft transplants [<a href="#rid41">41,42</a>]. However, incubation periods as short as five years and as long as 42 years have been reported in other patients [<a href="#rid41">41,43,44</a>].</p><p></p><p class="bulletIndent1">Proven surgical routes for transmission have now been eliminated following changes in procedures used to prepare dural grafts [<a href="#rid42">42</a>] and use of recombinant-derived hormones. An international CJD surveillance team reported that, in 2000, all incident cases of iCJD were due to long incubation periods from infections acquired before 1985 [<a href="#rid40">40</a>]. An exception may be the use of Lyodura dural grafts; those manufactured before 1987 (before new procedures were instituted) were not recalled internationally, and continued to be used until 1993 [<a href="#rid45">45</a>]. Cases of iCJD related to these grafts continue to accrue, in some cases 25 years after surgery. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfusion-related CJD</strong> – Available epidemiologic studies suggest that a history of preceding transfusion does not increase the risk of developing sCJD and no definite cases of primary transfusion-associated iCJD have been reported [<a href="#rid46">46,47</a>]. However, low levels of infectivity have been noted when whole blood, serum, or buffy coat derived from patients with sCJD is inoculated into animals. In one study of 436 individuals who received blood from 36 blood donors who subsequently developed CJD, no recipient developed CJD after 2096 person-years of follow-up [<a href="#rid48">48</a>]. There is one report of development of sCJD in a patient 8 to 10 months after albumin infusions during coronary artery bypass surgery [<a href="#rid49">49</a>]; however, this is likely to represent de novo sCJD.</p><p></p><p class="bulletIndent1">Transfusion-associated vCJD has been reported. Donor deferral programs, leukocyte depletion, and other risk reduction measures introduced primarily to prevent vCJD will likely further lower any risk of transfusion-associated prion disease. (See  <a class="medical medical_review" href="/z/d/html/5076.html" rel="external">"Variant Creutzfeldt-Jakob disease", section on 'Transfusion-related vCJD'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk for health care workers</strong> – Case-control studies have not found that health care professionals are at increased risk for CJD [<a href="#rid50">50-52</a>]. Physical contact with patients with CJD entails no risk of transmission and special precautions are not required in their routine care. However, special precautions should be employed in the handling of brain tissue; all materials and instruments used must be decontaminated according to established protocols [<a href="#rid53">53-55</a>]. (See  <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decontamination procedures</strong> – Prions are resistant to conventional physical decontamination methods, requiring procedures aimed at protein denaturation. It is important to keep instruments moist after use (either by immersion in water or a prionicidal detergent) because sterilization does not appear to be as effective on dried tissue. Prior to sterilization, instruments should be decontaminated in an automated dishwasher. Options for effective sterilization include [<a href="#rid56">56</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autoclaving at 134ºC for 18 minutes in a prevacuum sterilizer</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autoclaving at 132ºC for 1 hour in a gravity displacement sterilizer</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immersion in 1 N NaOH for 1 hour, followed by rinsing in water and autoclaving for 1 hour at 121ºC in a gravity displacement sterilizer or at 134ºC in a porous or prevacuum sterilizer</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immersion in 1 N NaOH for 1 hour, followed by heating in a gravity displacement sterilizer at 121ºC for 30 minutes, cleaning, and routine sterilization</p><p></p><p class="bulletIndent1">Instruments not fully accessible to the actions of the steam sterilant should be discarded. It should also be noted that the combination of NaOH and steam sterilization can be harmful to surgical instruments. However, flash sterilization or low-temperature methods for sterilization are ineffective.</p><p></p><p class="headingAnchor" id="H13"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H14"><span class="h2">Common symptoms and signs</span><span class="headingEndMark"> — </span>Although CJD can be clinically heterogeneous, a common feature is rapid neuropsychiatric decline with death usually occurring within one year of symptom onset [<a href="#rid57">57</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuropsychiatric symptoms</strong> are uniformly seen and may manifest as dementia, behavioral abnormalities, and deficits involving higher cortical function including aphasia, apraxia, and frontal lobe syndromes [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1">Impaired concentration, memory, and judgment are frequent early signs [<a href="#rid59">59</a>]. Mood changes such as apathy and depression are common; euphoria, emotional lability, and anxiety occur less frequently [<a href="#rid60">60</a>]. Sleep disturbances, particularly hypersomnia, but also insomnia, are also common, and may be a presenting sign [<a href="#rid61">61,62</a>]. Some patients have psychotic features, especially visual hallucinations [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1">With disease progression, dementia becomes dominant in most patients and can advance rapidly.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myoclonus</strong>, especially provoked by startle, is present in more than 90 percent of patients at some point during the illness but may be absent at presentation, even when dementia is profound. Sporadic CJD (sCJD) should always be considered in a patient with the combination of a rapidly progressive dementia and myoclonus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cerebellar manifestations</strong>, including nystagmus and ataxia, occur in approximately two-thirds of patients and are the presenting symptoms in 20 to 40 percent [<a href="#rid59">59</a>]. In particular, iatrogenic CJD (iCJD) related to human gonadotrophin and growth hormone treatment as well as to dura mater grafts has a propensity to manifest as a largely isolated cerebellar syndrome early in the disease course [<a href="#rid31">31,64,65</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Signs of corticospinal tract involvement</strong> develop in 40 to 80 percent of patients, including such findings as hyperreflexia, extensor plantar responses (Babinski sign), and spasticity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extrapyramidal signs</strong> such as hypokinesia, bradykinesia, dystonia, and rigidity also occur.</p><p></p><p>Younger patients with sCJD have clinical features that differ somewhat from more typical older patients. In one case series of 52 patients younger than 50 years, psychiatric symptoms, in particular affective symptoms, were more prominent and the clinical course more prolonged than in older patients [<a href="#rid66">66-68</a>]. </p><p>End-stage sCJD is generally characterized by akinetic mutism.<em> </em>Spasticity and myoclonus become more prevalent. Some patients develop seizures.</p><p class="headingAnchor" id="H1120495375"><span class="h2">Features atypical for CJD</span><span class="headingEndMark"> — </span>Some clinical findings, although compatible with CJD, should raise the suspicion of an alternative diagnosis, especially if they are among the more prominent features early in the illness. These include cranial nerve abnormalities and involvement of the peripheral nervous system. Disturbances of pupillary responses, trigeminal neuropathy, and vestibulocochlear dysfunction have all been reported in isolated cases but are not characteristic. Sensory signs and symptoms are a common clinical presentation in variant CJD (vCJD) but are less commonly a presenting symptom in sCJD.</p><p>Patients with iCJD from infected dura mater grafts have been noted to have a high frequency of clinical manifestations that relate to the anatomic placement of the graft [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Subtypes of sCJD</span><span class="headingEndMark"> — </span>A number of clinical subtypes of disease have been defined based upon neurologic findings reflecting predominant involvement of individual brain regions. Examples of these include forms with mainly visual (Heidenhain variant), cerebellar (Oppenheimer-Brownell variant), thalamic, striatal, cognitive, and affective features [<a href="#rid67">67,70</a>]. </p><p>At present, subtypes of sCJD are more usually classified postmortem according to the genotype of the <em>PRNP</em> gene at codon 129 and the molecular properties of the pathological prion protein (PrP<sup>Sc</sup>). The <em>PRNP</em> genotype may be homozygous or heterozygous for methionine (M) or valine (V) at codon 129. The PrP<sup>Sc</sup> type is determined by Western blot analysis and classified in the Parchi and Gambetti nomenclature as type 1 or type 2 depending on the size and electrophoretic mobility of the protease-resistant core fragment (PrP<sup>res</sup>) [<a href="#rid71">71,72</a>]. </p><p>Using this molecular classification, six clinical phenotypes of sCJD have been described [<a href="#rid72">72,73</a>] based on a series of 300 cases in North America and Europe [<a href="#rid72">72</a>], and an additional 2451 patients were analyzed for diagnostic test characteristics [<a href="#rid74">74</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MM1 and MV1</strong> account for approximately 70 percent of cases and correlate with the "classic CJD" phenotype with mid- to late-life onset, a rapidly progressive dementia with early and prominent myoclonus and ataxia, and a short duration of illness (mean 3.9 months).</p><p></p><p class="bulletIndent1">The MM1 phenotype is most commonly associated with periodic sharp wave complexes (PSWC) on electroencephalogram (EEG).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VV2</strong> (ataxic variant) accounts for approximately 10 percent of sCJD cases and presents with ataxia at onset, often as an isolated feature; late dementia; and a slightly longer duration of illness (mean seven to nine months) [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MV2</strong> (kuru plaque variant) accounts for another 10 percent of sCJD cases and presents with progressive dementia with prominent psychiatric features and longer duration (mean 17.1 months) [<a href="#rid76">76</a>]. PSWC are infrequently seen on EEG in patients with this subtype [<a href="#rid74">74,76-78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MM2</strong> can present as either a thalamic variant or a cortical variant. Some patients have a young age at onset, and the disease course is typically longer, with a median disease duration of 14 months in one study [<a href="#rid79">79</a>]. PSWC on EEG are more often absent in MM2 compared with other MM and MV subtypes [<a href="#rid72">72,74,77-79</a>]. The clinical features of MM2-type sCJD may resemble those of vCJD. (See  <a class="medical medical_review" href="/z/d/html/5076.html" rel="external">"Variant Creutzfeldt-Jakob disease", section on 'Clinical and demographic features'</a>.)</p><p></p><p class="bulletIndent1">The <strong>thalamic MM2</strong> variant (also referred to as sporadic fatal insomnia [sFI]) accounts for 2 percent of cases. The mean disease duration is 15.6 months. Insomnia, psychomotor hyperactivity, ataxia, and cognitive impairment are the predominant manifestations, resembling fatal familial insomnia (FFI) [<a href="#rid80">80</a>]. (See  <a class="medical medical_review" href="/z/d/html/5074.html" rel="external">"Diseases of the central nervous system caused by prions", section on 'Fatal familial insomnia'</a>.)</p><p></p><p class="bulletIndent1">The <strong>cortical MM2</strong> variant accounts for another 2 percent of cases, with a mean disease duration of 15.7 months. Dementia is the predominant manifestation, while cerebellar and visual signs are rarely described at presentation [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VV1</strong> accounts for 1 percent of cases and is notable for progressive dementia, younger age at onset, and longer duration (mean 15.3 months). A case series of nine patients with this subtype confirmed the slower, more prolonged course (median 21 months) [<a href="#rid82">82</a>]. None had PSWC on EEG, and cortical, rather than basal ganglia, abnormalities were more common on magnetic resonance imaging (MRI). Cerebrospinal fluid (CSF) real-time quaking-induced conversion (RT-QuIC) is negative in most sCJD VV1 cases [<a href="#rid83">83</a>].</p><p></p><p>The classification for PrP<sup>Sc</sup> is complicated by the existence of at least two nomenclatures, although the Parchi and Gambetti nomenclature for PrP<sup>Sc</sup> [<a href="#rid71">71,72</a>] described above is the most widely used. The alternate Collinge nomenclature distinguishes four rather than two PrP<sup>Sc</sup> subtypes [<a href="#rid84">84-86</a>]. The Collinge PrP<sup>Sc</sup> types 1 and 2 are thought to correspond with Parchi and Gambetti PrP<sup>Sc</sup> type 1, and Collinge types 3 and 4 with Parchi and Gambetti type 2 [<a href="#rid87">87</a>].</p><p>These molecular subtypes have also been associated with distinctive patterns of cerebral gene expression in CJD involving upregulation of genes involved in immune and stress responses and in cell death and downregulation of genes involved in synaptic function [<a href="#rid88">88</a>]. More than one molecular subtype may be present in 20 percent of individuals with sCJD, and PrP<sup>Sc </sup>type may be influenced by both genetic and brain region-specific factors [<a href="#rid89">89</a>].</p><p>The ongoing identification of rare molecular subtypes of CJD not included in these classification schemes may require their subsequent modification [<a href="#rid90">90</a>]. As an example, it has been increasingly recognized that some patients with CJD have both type 1 and type 2 PrP<sup>Sc</sup>, and that patients who have both types have a distinct clinical and pathologic phenotype [<a href="#rid91">91</a>]. In a series of 34 patients with the MM genotype, 20 individuals had both types (MM1+2) [<a href="#rid92">92</a>]. These patients had histopathologic features that were intermediate between patients with the MM1 and MM2 subtypes. A similar phenomenon has been demonstrated in VV1and VV2 cases [<a href="#rid93">93</a>].</p><p class="headingAnchor" id="H3066974353"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The evaluation of a patient with a rapidly progressive dementia includes neuroimaging, usually a brain MRI, EEG, and cerebrospinal fluid (CSF) evaluation. </p><p class="headingAnchor" id="H18"><span class="h2">Brain MRI</span><span class="headingEndMark"> — </span>Of the available neuroimaging modalities, MRI is the most helpful in the diagnosis of CJD [<a href="#rid94">94</a>]. MRI examination excludes other potential causes of rapidly progressive dementia and also can suggest that CJD is the underlying etiology.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protocol</strong> – The recommended MRI protocol for assessment of patients with suspected CJD includes T1-weighted axial images, T2-weighted axial images, fluid-attenuated inversion recovery (FLAIR) axial and sagittal images at 3 mm slice thickness, and diffusion-weighted images (DWI) [<a href="#rid95">95</a>]. Administration of contrast is not necessary for the evaluation of suspected CJD, but it may be helpful to exclude other diagnoses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Findings </strong>– Hyperintense signal on DWI, FLAIR, and T2-weighted images involving the cerebral cortex and corpus striatum caudate head and putamen is the most common pattern on MRI in patients with sporadic CJD (sCJD)  (<a class="graphic graphic_diagnosticimage graphicRef56359" href="/z/d/graphic/56359.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef127177" href="/z/d/graphic/127177.html" rel="external">image 2</a>) [<a href="#rid95">95-99</a>]. In particular, involvement of the superior frontal gyrus, superior parietal lobule, cingulate gyrus, and insular cortex is common; isolated limbic involvement is rare; and the perirolandic cortex is usually spared [<a href="#rid100">100-106</a>].</p><p></p><p class="bulletIndent1">DWI is the most sensitive MRI sequence for the detection of CJD-related lesions, especially for cortical and striatal changes. In autopsy studies, reduced diffusivity (ie, decreased water diffusion manifesting as hyperintense signal on DWI) correlates with areas of spongiform change or vacuolization of the neuropil [<a href="#rid107">107</a>].</p><p></p><p class="bulletIndent1">These findings are not entirely specific for CJD and may be confused with stroke, vasculitis, or reversible posterior leukoencephalopathy [<a href="#rid108">108,109</a>].</p><p></p><p class="bulletIndent1">MRI abnormalities may vary with the clinical syndrome and molecular subtype. Patients with suspected sCJD and increased T2 signal in the caudate and putamen are more likely to have early dementia, shorter survival, and VV2, MV2, or MM1 codon 129 genotypes than those without high basal ganglia signal [<a href="#rid61">61,110</a>]. Thalamic hyperintensities occur most often in VV2 and MV2 subtypes, and wide cortical signal increase is most common in the VV1 and MV1 subtypes  (<a class="graphic graphic_diagnosticimage graphicRef58441" href="/z/d/graphic/58441.html" rel="external">image 3</a>) [<a href="#rid110">110</a>]. Patients with the MM2 thalamic form of sCJD may have nearly normal brain by MRI and DWI, or show only late atrophy or white matter change [<a href="#rid111">111</a>]. sCJD molecular subtypes demonstrate fairly consistent lesion patterns on DWI that can be predicted with relative accuracy using an algorithm [<a href="#rid112">112</a>]. (See <a class="local">'Subtypes of sCJD'</a> above.)</p><p></p><p class="bulletIndent1">Atypical patterns on MRI are reported. Although DWI- and FLAIR-hyperintense signal in the cerebellum has been reported, cerebellar involvement on MRI is not typical despite the prevalence of cerebellar symptoms and neuropathological involvement in CJD. Cerebellar atrophy may be observed late in the disease [<a href="#rid101">101,113,114</a>]. Confluent hyperintense signal in the mesial and dorsal thalami on DWI, FLAIR, and T2-weighted MRI (the so-called "double hockey stick" or "pulvinar" sign) is the typical pattern for variant CJD (vCJD) but has been reported in rare cases of sCJD [<a href="#rid115">115</a>]. The MRI features of vCJD are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5076.html" rel="external">"Variant Creutzfeldt-Jakob disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic utility</strong> – MRI may be the most sensitive test in the early stages of disease, showing abnormalities even before the onset of characteristic clinical findings such as myoclonus and periodic sharp wave complexes (PSWC) seen on EEG [<a href="#rid100">100-102,116-118</a>]. In studies that used patients with other causes of rapidly progressive dementia as controls, MRI with DWI had sensitivities that ranged between 83 and 94 percent, higher than for EEG abnormalities and similar to 14-3-3 protein in the CSF [<a href="#rid100">100,101,119,120</a>]. Specificities in these studies ranged from 72 to 95 percent, requiring some caution in MRI interpretation [<a href="#rid121">121</a>]. These test characteristics also vary depending on the criteria used to interpret the brain MRI [<a href="#rid122">122</a>].</p><p></p><p class="bulletIndent1">Independent interpretation of MRI films in 193 patients with CJD by three radiologists was associated with 82 to 86 percent agreement as to whether findings were typical or atypical for CJD [<a href="#rid123">123</a>]. High degrees of interrater reliability have been found in other studies as well [<a href="#rid101">101</a>].</p><p></p><p class="bulletIndent1">The sensitivity and specificity of MRI vary with the stage of the disease as discussed below. While an abnormal MRI supports the diagnosis in the correct clinical setting, a negative MRI does not exclude CJD when the clinical case is compelling and particularly if DWI is not performed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evolution of MRI abnormalities</strong> – Case series document a characteristic progression of MRI signal change from early to late disease in sCJD and iatrogenic CJD (iCJD). Although the data are limited to small observational studies, the following MRI patterns have been reported [<a href="#rid95">95,102,108,124</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Early CJD is characterized by increased DWI signal in cortex, corpus striatum (caudate and anterior putamen), or both. The abnormal signal may be unilateral or bilateral; focal, multifocal, or diffuse; and asymmetrical or symmetrical. The corresponding apparent diffusion coefficient (ADC) values are decreased, suggesting restricted diffusion from spongiform encephalopathy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intermediate CJD is characterized on DWI by progression of unilateral/asymmetrical lesions to greater contralateral/symmetrical involvement and progression of caudate lesions to involve the putamen  (<a class="graphic graphic_diagnosticimage graphicRef56359" href="/z/d/graphic/56359.html" rel="external">image 1</a>). FLAIR images are very likely to show high signal abnormalities, but with less prominence than DWI. Generalized atrophy and ventricular dilatation may be apparent on all sequences.</p><p></p><p class="bulletIndent2">Although primarily a disease of gray matter, sCJD can cause secondary white matter abnormalities in early to intermediate stages as demonstrated on both MRI and neuropathologic studies [<a href="#rid125">125,126</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Late or terminal CJD is characterized by prominent generalized atrophy and ventricular dilatation [<a href="#rid97">97,101,114</a>]. Limited data suggest that loss of abnormal cortical and basal ganglionic DWI high signal may occur in some but not all cases.</p><p></p><p class="bulletIndent1">In the early and intermediate stages of CJD, FLAIR appears to be more sensitive than T2 imaging [<a href="#rid127">127</a>], but sensitivity and conspicuity are best with DWI  (<a class="graphic graphic_diagnosticimage graphicRef56359" href="/z/d/graphic/56359.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef58441" href="/z/d/graphic/58441.html" rel="external">image 3</a>). The relative sensitivities of these methods in late CJD are unclear. </p><p></p><p class="headingAnchor" id="H21"><span class="h2">Other neuroimaging studies</span><span class="headingEndMark"> — </span>MRI is superior to computed tomography (CT) in detecting abnormalities in patients with sCJD [<a href="#rid94">94,95</a>]. A head CT scan is generally normal and serves mainly to exclude other diagnoses. However, serial CT scans performed over several months may show rapid ventricular enlargement and progressive cortical atrophy in some patients [<a href="#rid128">128</a>].</p><p>Abnormal 18-F fluorodeoxyglucose positron emission tomography (FDG-PET), single-photon emission computed tomography (SPECT), and MRI spectroscopy have also been described in patients with sCJD [<a href="#rid129">129-131</a>]. However, these tests have not been evaluated sufficiently to assess their clinical utility [<a href="#rid94">94</a>]. Although there is a correlation between FDG-PET findings and neuropathology in cortical areas, as well as with clinical symptoms, the diagnostic utility of these findings is likely nonspecific [<a href="#rid111">111,132,133</a>].</p><p>PET scans utilizing amyloid tracers (<sup>18</sup>F-florbetaben) may crossreact with prion proteins as found in one case [<a href="#rid134">134</a>]; however, tau tracers (eg, <sup>18</sup>F-AV-1451) do not appear to demonstrate positive results in sCJD [<a href="#rid135">135</a>]. sCJD may also result in an abnormal <sup>123</sup>I-FP-CIT SPECT (DaTscan) [<a href="#rid136">136</a>].</p><p class="headingAnchor" id="H22"><span class="h2">Electroencephalogram</span><span class="headingEndMark"> — </span>A characteristic EEG pattern of periodic synchronous bi- or triphasic PSWC is observed in 67 to 95 percent of patients with sCJD at some time during the course of the illness. This finding provides supportive but not definitive evidence for CJD. </p><p>The PSWC typical of sCJD are characterized by the following features [<a href="#rid137">137</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Strictly periodic cerebral potentials, the majority with a duration of 100 to 600 milliseconds and an intercomplex interval of 500 to 2000 milliseconds</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Generalized and/or lateralized complexes </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At least five repetitive intervals with a duration difference of &lt;500 milliseconds required to exclude semiperiodic activity</p><p></p><p>PSWC with these characteristics have a very high specificity for the diagnosis of sCJD and low interobserver variability. Studies have found that objective EEG criteria for sCJD have a sensitivity and specificity of approximately 65 and 90 percent, respectively, and positive and negative predictive values of 95 and 49 percent, respectively [<a href="#rid137">137,138</a>]. False-positive EEG results have been reported in Alzheimer disease and vascular dementia.</p><p>PSWC are helpful in the differentiation of sCJD from other prion disease [<a href="#rid138">138</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>PSWC are occasionally found in patients with genetic CJD (gCJD), most commonly in patients who have the codon 200 mutation [<a href="#rid139">139</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PSWC are not found in patients with vCJD, kuru, Gerstmann-Sträussler-Scheinker syndrome (GSS), or fatal familial insomnia (FFI). </p><p></p><p>Other factors may contribute to the sensitivity of the PSWC finding:</p><p class="bulletIndent1"><span class="glyph">●</span>Disease duration – PSWC may not be recorded in the initial stages of the illness. The probability of recording PSWC corresponds to the amount of neuronal loss, and serial EEG recording may be useful in patients suspected of having sCJD when initial EEG recordings are negative [<a href="#rid140">140</a>]. PSWC typically disappear in later stages of sCJD, which are characterized by low voltage activity followed by electrocerebral inactivity [<a href="#rid74">74,141</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Molecular subtype – PSWC are less common in the thalamic variant of MM2 sCJD (ie, sporadic fatal insomnia [sFI]), as well as the MV2 and VV2 subtypes [<a href="#rid74">74,76,142</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age – One analysis of 2083 patients with pathologically confirmed CJD found that the presence of PSWC steadily increased with age, from 22 percent in individuals &lt;50 years old to 67 percent in those &gt;70 years [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drugs such as barbiturates and benzodiazepines can mask PSWC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>iCJD may also be less likely to be associated with PSWC [<a href="#rid64">64</a>].</p><p></p><p>The mechanism of PSWC is speculative, but attention has been called to the similarity of PSWC in sCJD to the EEG pattern seen in preterm newborns [<a href="#rid138">138,140,143</a>]; cortical degeneration due to sCJD may erode the normal physiologic sleep architecture, which is replaced by activity driven from an underlying midline pacemaker, possibly thalamic, and involved with the ascending reticulothalamocortical activating system [<a href="#rid144">144</a>].</p><p class="headingAnchor" id="H23"><span class="h2">Cerebrospinal fluid protein markers</span></p><p class="headingAnchor" id="H3355898764"><span class="h3">Real-time quaking-induced conversion</span><span class="headingEndMark"> — </span>Real-time quaking-induced conversion (RT-QuIC) is an assay in which disease-associated prion protein (PrP<sup>Sc</sup>) initiates a conformational transition in recombinant prion protein (recPrP), resulting in the formation of amyloid that can be monitored in real time [<a href="#rid145">145</a>]. (See  <a class="medical medical_review" href="/z/d/html/5074.html" rel="external">"Diseases of the central nervous system caused by prions", section on 'Detection of abnormal prion protein'</a>.)</p><p>In one series with a validation cohort, the sensitivity and specificity of RT-QuIC were 87 to 91 percent and 98 to 100 percent, respectively [<a href="#rid146">146</a>]. In a United States sample, sensitivity and specificity of RT-QuIC were 92 to 95 percent and 98.5 to 100 percent, respectively [<a href="#rid147">147</a>]. Diagnostic sensitivity is higher in common sCJD molecular subtypes (eg, MM1 and MV1) and lower in less common subtypes (eg, VV1, MM2-C, and sFI) [<a href="#rid83">83</a>]. The <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cjdsurveillance.com%2F&amp;token=8k3jtx9Yp6vcMbO4vu%2BxLreTDhw508uBYf2QMylcaeOxMouc5FE6g55oObg%2BNTfp&amp;TOPIC_ID=5084" target="_blank">National Prion Disease Pathology Surveillance Center</a> based at Case Western Reserve University is the only clinical laboratory in the United States that performs RT-QuIC. CSF samples submitted to the Center also undergo 14-3-3 and tau analyses. </p><p>In one preliminary study that included 31 patients with CJD, RT-QuIC testing of olfactory epithelium obtained from nasal brushings was more sensitive (97 versus 77 percent) and similarly specific (100 percent) when compared with CSF testing; however, RT-QuIC on nasal brushings is not performed clinically in the United States [<a href="#rid148">148,149</a>]. </p><p class="headingAnchor" id="H24"><span class="h3">14-3-3 protein</span><span class="headingEndMark"> — </span>Detection of 14-3-3 protein in CSF should be considered an adjunctive rather than diagnostic test for the diagnosis of prion diseases as studies have reported mixed results regarding its sensitivity and specificity [<a href="#rid74">74,150-154</a>]. One systematic review reported an overall sensitivity of 92 percent and a specificity of 80 percent in diagnosing sCJD [<a href="#rid155">155</a>]. A specificity of 80 percent in a disease with a prevalence as low as that of CJD means that the vast majority of positive tests will represent false positives.</p><p>A negative test does not exclude the diagnosis, especially in cases of possible gCJD or nonclassical sCJD (eg, MM2 and MV2) in which the sensitivity of the test may be as low as 60 percent [<a href="#rid74">74,76-78</a>]. Other reports have found that the sensitivity may be lower in the very early stages and also the late stages of disease [<a href="#rid74">74,78</a>]. </p><p>While positive results are frequent in nonprion diseases, a positive test slightly increases the probability of CJD when other clinical features are suggestive but not diagnostic [<a href="#rid155">155</a>]. False-positive elevations in CSF 14-3-3 have been noted in patients with a variety of neurologic diseases including herpes simplex encephalitis, hypoxic encephalopathy, cerebral metastases, paraneoplastic disease, and metabolic encephalopathies [<a href="#rid78">78,151,156-158</a>]. False-positive results are less likely, but have been described in neurodegenerative disease, including Alzheimer disease [<a href="#rid78">78,158</a>]. </p><p>One investigation examined expression of this protein in cell cultures of neural and nonneural tissues and found the protein in all cell types, suggesting that the protein may be a marker of brain cell death rather than CJD [<a href="#rid157">157</a>]. Seven distinct isoforms of the 14-3-3 protein, with two phosphorylated subtypes, have been found in neurons. It has been suggested that CSF assays for one or more of the specific isoforms may have improved specificity for distinguishing sCJD from other dementias compared with the standard commercial 14-3-3 assay [<a href="#rid159">159,160</a>]. However, elevated CSF levels of most 14-3-3 isoforms are described in a variety of other conditions including Alzheimer disease, vascular dementia, metabolic and viral encephalopathies, and paraneoplastic syndromes, indicating that none of these assays will be diagnostic of prion disease. </p><p class="headingAnchor" id="H686019915"><span class="h3">Tau protein</span><span class="headingEndMark"> — </span>An elevated tau level (&gt;1150 picogram/mL) has superior accuracy and specificity when compared with 14-3-3 protein as a diagnostic test for CJD, although both tests produce significant numbers of false-negative and false-positive results [<a href="#rid161">161-163</a>].</p><p>In another study, patients with CJD were found to have elevated CSF tau levels, but not phosphorylated tau; an elevated ratio of total tau to phosphorylated tau levels had a very high specificity for CJD [<a href="#rid160">160,164</a>]. </p><p>CSF total tau is also a prognostic marker for survival time in sCJD when used alone or with other variables (eg, age, codon 129, etc) [<a href="#rid165">165,166</a>].</p><p class="headingAnchor" id="H25"><span class="h3">Other CSF findings and tests</span><span class="headingEndMark"> — </span>The CSF contains no cells and usually has normal glucose. An elevated CSF protein occurs in approximately 40 percent of patients with CJD [<a href="#rid121">121</a>]. An elevated white blood cell count, the presence of oligoclonal bands, or immunoglobulin G (IgG) index should prompt other diagnostic considerations such as autoimmune encephalitis.</p><p>A variety of other CSF diagnostic tests have been reported in small series, including S100 protein [<a href="#rid79">79</a>], neuron-specific enolase [<a href="#rid163">163,167</a>], and thymosin β4 [<a href="#rid168">168</a>]. Studies are also examining the diagnostic utility of CSF test combinations in detecting CJD [<a href="#rid78">78,154,169</a>]. The presence of any of the following markers was associated with good sensitivity of CSF analysis for detecting CJD: 14-3-3, tau, S100, and neuron-specific enolase [<a href="#rid78">78</a>]. However, the sensitivity still remained low (50 to 85 percent) for the nonclassical MV2 subtype of CJD, and specificity was also low overall (57 to 88 percent). </p><p class="headingAnchor" id="H26"><span class="h2">Other laboratory findings</span><span class="headingEndMark"> — </span>Routine laboratory studies are typically normal in CJD. In one case series, elevated plasma levels of several acute phase reactants were noted in patients with CJD [<a href="#rid170">170</a>]. </p><p class="headingAnchor" id="H27"><span class="h2">Investigational studies</span><span class="headingEndMark"> — </span>Establishing the diagnosis of prion diseases by detecting abnormal prions outside of the central nervous system (CNS) remains a research goal [<a href="#rid171">171</a>]. Investigators have examined a variety of techniques to make the diagnosis on samples from skin, nasal mucosa, and peripheral nerves as well as spleen and skeletal muscle [<a href="#rid172">172-179</a>]. As yet, none of these assays have sufficient evidence of diagnostic utility to be recommended for clinical practice. </p><p>Prion protein diagnostic assays performed on blood samples are in development [<a href="#rid146">146,180</a>].</p><p class="headingAnchor" id="H3159407212"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>CJD must be distinguished from other dementias. Occasionally Alzheimer disease, dementia with Lewy bodies, and corticobasal degeneration are associated with myoclonus and a more rapidly progressive course than is typical, and are therefore mistaken for CJD. </p><p>A limited number of conditions that are relatively uncommon produce a syndrome of rapidly progressive dementia that can be mistaken for CJD. While these are uncommon, some are treatable, and therefore the evaluation should be thorough. Among others, the differential diagnosis should include paraneoplastic syndromes and autoimmune encephalitis. Thus, neuroimaging and cerebrospinal fluid (CSF) analysis is essential.</p><p>Early in the disease course, a primary psychiatric disorder may be suspected, as behavior and personality changes may be prominent and obscure accompanying cognitive deficits [<a href="#rid63">63</a>]. However, as the disease progresses and neurologic signs become more prominent, evaluation for a dementia syndrome is generally undertaken.</p><p class="headingAnchor" id="H2409799128"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>CJD should be suspected in patients who present with rapidly progressive dementia syndrome, particularly if accompanied by myoclonus, ataxia, and/or visual disturbances. Other potentially treatable disorders must be excluded.</p><p>Pathological studies of brain material to detect protease-resistant PrP<sup>Sc</sup> (PrP<sup>res</sup>) remain the gold standard for the diagnosis of prion diseases. Although neuropathologic examination can be achieved via brain biopsy, a probable diagnosis of sporadic CJD (sCJD) can be made with noninvasive testing and is generally sufficient.</p><p class="headingAnchor" id="H1944415955"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>Criteria for the diagnosis of sCJD have been proposed [<a href="#rid2">2,181-183</a>]. Appropriate clinical and laboratory features generally are sufficient for a "probable" diagnosis of sCJD, while a definitive diagnosis requires neuropathologic confirmation [<a href="#rid171">171</a>].</p><p>The Centers for Disease Control and Prevention (CDC) outline two criteria for probable sCJD [<a href="#rid184">184</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Neuropsychiatric disorder with a positive real-time quaking-induced conversion (RT-QuIC) test, <strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Progressive dementia, <strong>and</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At least two out of the following four clinical features: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Myoclonus</p><p class="bulletIndent3"><span class="glyph">-</span>Visual or cerebellar disturbance</p><p class="bulletIndent3"><span class="glyph">-</span>Pyramidal or extrapyramidal dysfunction</p><p class="bulletIndent3"><span class="glyph">-</span>Akinetic mutism </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Supportive findings on one or more of the following tests:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A typical EEG (eg, periodic sharp wave complexes [PSWC]) during an illness of any duration</p><p class="bulletIndent3"><span class="glyph">-</span>Positive 14-3-3 cerebrospinal fluid (CSF) assay with a clinical duration to death less than two years</p><p class="bulletIndent3"><span class="glyph">-</span>MRI showing hyperintensity in caudate nucleus/putamen and/or in at least two cortical regions (temporal, parietal, and occipital) on diffusion-weighted imaging (DWI) or fluid-attenuated inversion recovery (FLAIR)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Routine investigations should not suggest an alternative diagnosis</p><p></p><p class="headingAnchor" id="H3347662286"><span class="h2">Neuropathology</span><span class="headingEndMark"> — </span>While neuropathology provides a definitive diagnosis of CJD, a brain biopsy is not required in most patients and should only be undertaken with the purpose of excluding an alternative treatable etiology rather than to provide definitive evidence of prion disease [<a href="#rid185">185</a>]. In particular, a brain biopsy is generally not necessary in the setting of a positive RT-QuIC result, given its high specificity for sCJD, unless an alternative diagnosis is being entertained.</p><p>However, autopsies are important to definitively diagnose prion disease and determine the precise phenotype. Autopsy is especially important for surveillance reasons to monitor the possibility of acquired cases and possible emerging prion diseases (eg, the potential transmission of chronic wasting disease from deer/elk to humans). Autopsies of suspected CJD cases can be arranged through a CDC-funded autopsy program at the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cjdsurveillance.com%2F&amp;token=8k3jtx9Yp6vcMbO4vu%2BxLreTDhw508uBYf2QMylcaeOxMouc5FE6g55oObg%2BNTfp&amp;TOPIC_ID=5084" target="_blank">National Prion Disease Pathology Surveillance Center</a>.</p><p>A definitive diagnosis of sCJD requires the clinical and laboratory features described above and one or more of the following neuropathologic findings, combined with the absence of <em>PRNP</em> gene mutations:</p><p class="bulletIndent1"><span class="glyph">●</span>Loss of neurons, gliosis, spongiform degeneration, or plaques positive for PrP<sup>Sc</sup> on histopathology of brain tissue</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positive PrP<sup>Sc</sup> staining following pretreatment of brain tissue with proteinase K to destroy PrP<sup>C</sup> (normal prion protein) reactivity</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positive immunoblotting of brain tissue extracts for PrP<sup>Sc</sup> after treatment with proteinase to destroy PrP<sup>C</sup> reactivity</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transmission of characteristic neurodegenerative disease to experimental animals</p><p></p><p>Immunohistochemistry techniques such as enzyme-linked immunosorbent assay (ELISA) and conformation-dependent immunoassay (CDI) can detect the presence and levels of disease-causing PrP<sup>Sc</sup> in human brain tissue at autopsy or in biopsy samples. The CDI method has a higher sensitivity for the diagnosis of sCJD disease compared with routine neuropathologic examination and immunohistochemistry [<a href="#rid186">186</a>], but its specificity remains to be established. (See  <a class="medical medical_review" href="/z/d/html/5074.html" rel="external">"Diseases of the central nervous system caused by prions", section on 'Detection of abnormal prion protein'</a>.)</p><p>On gross examination, most cases show no more than expected age-associated brain atrophy, although marked atrophic changes may be seen in patients with long survivals.</p><p>The main histologic features of prion disease are  (<a class="graphic graphic_picture graphicRef80949" href="/z/d/graphic/80949.html" rel="external">picture 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spongiform change</strong> – The vacuoles that create the spongiform change in CJD are round and between 20 to 50 microns in diameter  (<a class="graphic graphic_picture graphicRef70414" href="/z/d/graphic/70414.html" rel="external">picture 2</a>). Electron microscopy has revealed that the vacuolization is an intraneuronal process, and that synaptic loss is common.</p><p></p><p class="bulletIndent1">Neurodegenerative and cerebrovascular diseases associated with severe neuronal loss can also produce status spongiosus as a common feature in end stages. This is a coarse microvacuolization with obvious severe neuronal loss and reactive astrocytosis. The vacuoles are larger and more irregular than those seen in CJD. Spongiform change in frontotemporal dementias is usually restricted to the upper cortical layers and to the frontal and temporal lobes, while full thickness spongiosis in dementia with Lewy bodies is usually restricted to the medial temporal lobes. Acute hypoxic-ischemic and other metabolic encephalopathies can also give this microscopic appearance, although with ischemia, eosinophilic neuronal degeneration parallels the severity of the edematous changes. Finally, inadequate tissue fixation or poor processing can cause artefactual changes that resemble prion vacuoles, but are characteristically much more obvious surrounding cell bodies and blood vessels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reactive gliosis </strong>– Reactive gliosis<strong> </strong>without inflammation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Accumulation of the abnormal prion protein</strong> – Accumulation of the prion protein is detected by immunohistochemical techniques  (<a class="graphic graphic_picture graphicRef50744" href="/z/d/graphic/50744.html" rel="external">picture 3</a>). The prion protein can be distributed in several patterns: synaptic, perineuronal, perivacuolar, and plaque-like.</p><p></p><p class="bulletIndent1">Certain prion protein diseases, including sCJD-MV2, kuru, Gerstmann-Sträussler-Scheinker syndrome (GSS), and variant CJD (vCJD), are characterized by prion plaques visible on routine hematoxylin and eosin stain. (See  <a class="medical medical_review" href="/z/d/html/5076.html" rel="external">"Variant Creutzfeldt-Jakob disease"</a> and  <a class="medical medical_review" href="/z/d/html/5074.html" rel="external">"Diseases of the central nervous system caused by prions", section on 'Neuropathology'</a>.)</p><p></p><p class="bulletIndent1">The pattern and distribution of prion protein deposition may be specific to the subtype of sCJD (see <a class="local">'Subtypes of sCJD'</a> above). As examples, MM1 and MV1 subtypes have been associated with the synaptic pattern of prion protein immunostaining; MV2 and VV2 with plaque-like and perineuronal immunoreactivity, especially prominent in the deep cortical layers, basal ganglia, and cerebellum; and MM2 with perivacuolar and coarse plaque-like formations [<a href="#rid187">187</a>]. Iatrogenic CJD (iCJD) related to dura mater grafts has also been associated with plaque formation [<a href="#rid64">64</a>].</p><p></p><p class="headingAnchor" id="H29"><span class="h1">TREATMENT AND PROGNOSIS</span><span class="headingEndMark"> — </span>There is no effective treatment for CJD, which is uniformly fatal. Death usually occurs within one year of symptom onset, with a median disease duration of six months [<a href="#rid57">57,188,189</a>].</p><p class="headingAnchor" id="H1843434452"><span class="h2">Supportive and symptomatic treatment</span><span class="headingEndMark"> — </span>No effective treatment has been identified for human prion diseases, which are universally fatal [<a href="#rid190">190</a>]. Care for patients with prion disease is supportive and includes [<a href="#rid185">185</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Early and effective communication with family. Provision of vetted educational materials may be particularly helpful in the case of sporadic CJD (sCJD), as the diagnosis may be unfamiliar to patients and their families or other caregivers. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcjdfoundation.org%2F&amp;token=Q6R3TQKhk5jss%2FLgNuSevvCE3YoE5R17K9hXVZz2qtXU9U9rg7kJqPNEqR8W3N9e&amp;TOPIC_ID=5084" target="_blank">CJD Foundation</a> is a resource. (See <a class="local">'Information for patients'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Social services referral to coordinate care needs, arrange for hospice evaluation, and counsel families or other caregivers on end-of-life and financial matters. Referral is appropriate at the time of diagnosis.</p><p></p><p class="bulletIndent1">Many patients with CJD are working at the time of disease onset and may be eligible for disability payments. In the United States, CJD is one of the diseases that allows "fast track" eligibility for benefits. Further information is available at the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.ssa.gov%2Fcompassionateallowances&amp;token=q%2BSdfKw1WWTohwBj8j%2BEoFwhXyyfzAWYKCHwsasg6XWmmSAyQmz2G63y18xuUMNtif8OG6o5SNpYF1%2Br3KB3Qw%3D%3D&amp;TOPIC_ID=5084" target="_blank">Social Security Administration website</a>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Capacity and competence assessment as relates to health care and financial decisions. (See  <a class="medical medical_review" href="/z/d/html/98592.html" rel="external">"Assessment of decision-making capacity in adults"</a>.)</p><p></p><p>Symptomatic treatment is often appropriate for management of distressing or disabling neuropsychiatric symptoms. Nonpharmacologic as well as pharmacologic options are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5082.html" rel="external">"Management of neuropsychiatric symptoms of dementia"</a>.)</p><p>Myoclonus may respond to benzodiazepines (eg, <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a>) as well as to certain antiseizure medications such as <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a> and <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>. Dosing and administration of these agents are described separately. (See  <a class="medical medical_review" href="/z/d/html/4888.html" rel="external">"Treatment of myoclonus"</a>.)</p><p>Treatment with cholinesterase inhibitors or N-methyl-D-aspartate (NMDA) receptor antagonists are not expected to be useful in sCJD and are not administered, though cholinesterase inhibitors reportedly help alleviate psychotic symptoms in some cases [<a href="#rid63">63</a>].</p><p>Other aspects of the care of patients with advanced dementia are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/86250.html" rel="external">"Care of patients with advanced dementia"</a>.)</p><p class="headingAnchor" id="H2502691747"><span class="h2">Investigational treatments</span><span class="headingEndMark"> — </span>A number of potential therapies have been investigated in sCJD. While hampered by study limitations including heterogenous patient populations and small trial sizes, these studies have not demonstrated a treatment effect including symptom improvement or longer survival. Investigated therapies have included:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Flupirtine</strong> – Flupirtine maleate is a centrally acting, nonopioid analgesic that has displayed cytoprotective activity in vitro in neurons inoculated with a prion protein fragment [<a href="#rid191">191</a>]. The mechanism of neuroprotective action is unknown, but it may involve upregulation of the antiapoptotic protein Bcl-2 [<a href="#rid191">191,192</a>]. Alternatively, its NMDA antagonist properties might limit glutamate-mediated neurotoxicity [<a href="#rid193">193</a>].</p><p></p><p class="bulletIndent1">In a European study, 28 patients with CJD were randomly assigned to treatment with flupirtine or placebo [<a href="#rid194">194</a>]. Flupirtine treatment was initiated at 100 mg per day, and increased over three days to a maintenance dose of 300 to 400 mg per day, which was continued for a median treatment duration of 29 days. There was no significant effect of flupirtine treatment on survival time compared with placebo. However, the patients treated with flupirtine performed significantly better on the cognitive part of the Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog). Flupirtine-treated patients also did better on the Mini-Mental State Examination, but the difference did not reach statistical significance. Caregiver's impressions were also significantly better in the flupirtine-treated group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pentosan polysulfate</strong> – <a class="drug drug_general" data-topicid="9755" href="/z/d/drug information/9755.html" rel="external">Pentosan polysulfate</a> (PPS) is a heparin mimetic thought to interfere with the conversion of PrP<sup>C</sup> to PrP<sup>Sc</sup>. Because it does not cross the blood-brain barrier, it must be given intraventricularly. A United Kingdom observational study examining the use of PPS in several prion diseases demonstrated longer than expected survival times on some patients [<a href="#rid195">195</a>]. Similarly, a study conducted in Japan demonstrated a possible increase in survival time in some cases [<a href="#rid196">196</a>]. However, no improvement in clinical features was noted in either study, and treatment was complicated by frequent subdural effusions. This treatment is not generally considered at present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quinacrine </strong>– Quinacrine and <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">chlorpromazine</a>, specific derivatives of acridine and phenothiazine, were found to inhibit PrP<sup>Sc</sup> formation in a cultured neuroblastoma cell line (ScN2a) chronically infected with prions [<a href="#rid197">197</a>]. Quinacrine was approximately 10 times more potent than chlorpromazine in inhibiting scrapie formation in culture.</p><p></p><p class="bulletIndent1">Observational studies and two randomized trials did not find an overall survival benefit for quinacrine for either sCJD or variant CJD (vCJD) [<a href="#rid198">198-200</a>]. However, one trial in 54 patients with sCJD did demonstrate slower decline in the first two months of treatment on two of three cognitive variables in sCJD [<a href="#rid200">200</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Doxycycline</strong> – The tetracyclines <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> and <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> have demonstrated efficacy in in vitro and animal models of prion disease by presumably preventing protein misfolding of the pathologic form of the prion protein [<a href="#rid201">201</a>].</p><p></p><p class="bulletIndent1">In one trial of 121 patients with CJD, no survival benefit was observed for treatment with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> [<a href="#rid202">202</a>]. In a subsequent meta-analysis that included largely observational data, a slight increase in survival time in the doxycycline treatment group was observed (hazard ratio [HR] 0.63, 95% CI 0.402-0.999), particularly if given early in the disease course in some subjects [<a href="#rid203">203</a>]. Given the unclear clinically meaningful benefit of this study, doxycycline is generally not routinely prescribed. A clinical trial examining the possibility of using doxycycline as a prophylactic treatment for asymptomatic mutation carriers of the fatal familial insomnia (FFI) mutation is currently in progress [<a href="#rid204">204</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic therapies/engineering</strong> – Given the importance of the PrP<sup>C</sup> to prion disease, some future treatments are focusing on genetic therapies/genetic engineering designed to lower the expression of PrP<sup>C</sup> (eg, antisense oligonucleotides). Theoretically, this treatment approach would be effective in sCJD and genetic CJD (gCJD) [<a href="#rid205">205,206</a>].</p><p></p><p class="headingAnchor" id="H31596205"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83084.html" rel="external">"Patient education: Creutzfeldt-Jakob disease (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H9729802"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Creutzfeldt-Jakob disease (CJD) is the most frequent of the human prion diseases, although it is still rare. Approximately one new case of sporadic CJD (sCJD) occurs per 1,000,000 population per year. The mean age of onset is approximately 62 years. (See <a class="local">'Epidemiology'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – sCJD is the most common prion disease; the prion protein in sCJD is thought to be generated endogenously rather than acquired. Iatrogenic CJD (iCJD) has followed administration of cadaveric human pituitary hormones, dural graft transplants, and other procedures and is rare now that these vectors have been removed from the health care system. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Rapidly progressive mental deterioration, often with behavioral abnormalities, and myoclonus are cardinal clinical manifestations of sCJD. Extrapyramidal signs such as hypokinesia and cerebellar manifestations are also common. (See <a class="local">'Common symptoms and signs'</a> above.)</p><p></p><p class="bulletIndent1">Clinical phenotypes of sCJD have been associated with molecular subtypes determined by the prion protei<em>n (PRNP</em>) gene codon 129 genotype and the pathologic prion protein (<sup>Pr</sup>P<sup>Sc</sup>) type. (See <a class="local">'Subtypes of sCJD'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – CJD is distinguished from more common causes of dementia by its rapidly progressive course with prominent myoclonus and gait disturbance. Other autoimmune, infectious, malignant, and toxic-metabolic etiologies should be excluded before settling on a diagnosis of CJD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong> – A classic clinical presentation, exclusion of other causes, and corroborating findings on brain MRI, EEG, and cerebrospinal fluid (CSF) are sufficient in most cases to establish CJD as the probable diagnosis. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>MRI should be performed according to a suggested protocol and typically shows abnormal hyperintense signal in the putamen and head of the caudate and in a cortical ribboning pattern of the cortex. Sensitivity and specificity for typical MRI findings range between 83 to 92 percent and 87 to 95 percent, respectively. (See <a class="local">'Brain MRI'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A finding of periodic sharp wave complexes (PSWC) on EEG has a high specificity for the diagnosis of CJD, but a low sensitivity. (See <a class="local">'Electroencephalogram'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tests on CSF samples that are sent to the National Prion Disease Pathology Surveillance Center (tau, real-time quaking-induced conversion [RT-QuIC], and 14-3-3 protein) can support the diagnosis of CJD. CSF RT-QuIC is the most sensitive and specific CSF diagnostic test for sCJD. The 14-3-3 protein test in CSF is a nonspecific test finding for CJD. (See <a class="local">'Cerebrospinal fluid protein markers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuropathology</strong> – While neuropathologic examination is the gold-standard test, brain biopsies are often unnecessary. However, autopsies are important to definitively diagnose prion disease and determine its specific phenotype. This is especially important for surveillance and can be arranged through a Centers for Disease Control and Prevention (CDC)-funded autopsy program at the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cjdsurveillance.com%2F&amp;token=8k3jtx9Yp6vcMbO4vu%2BxLreTDhw508uBYf2QMylcaeOxMouc5FE6g55oObg%2BNTfp&amp;TOPIC_ID=5084" target="_blank">National Prion Disease Pathology Surveillance Center</a>. (See <a class="local">'Neuropathology'</a> above.)</p><p></p><p class="bulletIndent1">The main histologic features of prion disease are spongiform change, reactive gliosis without inflammation, and accumulation of the abnormal prion protein detected by immunohistochemical techniques. (See <a class="local">'Neuropathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment and prognosis</strong> – There is no effective treatment for CJD, which is uniformly fatal. Death usually occurs within one year of symptom onset. Supportive and symptomatic treatments are advised. (See <a class="local">'Treatment and prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H194589759"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Henry G Brown, MD, PhD, and John M Lee, MD, PhD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Puoti G, Bizzi A, Forloni G, et al. Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurol 2012; 11:618.</a></li><li><a class="nounderline abstract_t">Masters CL, Harris JO, Gajdusek DC, et al. Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol 1979; 5:177.</a></li><li><a class="nounderline abstract_t">Ladogana A, Puopolo M, Croes EA, et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology 2005; 64:1586.</a></li><li><a class="nounderline abstract_t">Klug GM, Wand H, Simpson M, et al. Intensity of human prion disease surveillance predicts observed disease incidence. J Neurol Neurosurg Psychiatry 2013; 84:1372.</a></li><li><a class="nounderline abstract_t">Brown P, Cathala F, Raubertas RF, et al. The epidemiology of Creutzfeldt-Jakob disease: conclusion of a 15-year investigation in France and review of the world literature. Neurology 1987; 37:895.</a></li><li><a class="nounderline abstract_t">Monreal J, Collins GH, Masters CL, et al. Creutzfeldt-Jakob disease in an adolescent. J Neurol Sci 1981; 52:341.</a></li><li><a class="nounderline abstract_t">de Silva R, Findlay C, Awad I, et al. Creutzfeldt-Jakob disease in the elderly. Postgrad Med J 1997; 73:557.</a></li><li><a class="nounderline abstract_t">Johnson RT, Gonzalez RG, Frosch MP. Case records of the Massachusetts General Hospital. Case 27-2005. An 80-year-old man with fatigue, unsteady gait, and confusion. N Engl J Med 2005; 353:1042.</a></li><li><a class="nounderline abstract_t">Ladogana A, Puopolo M, Poleggi A, et al. High incidence of genetic human transmissible spongiform encephalopathies in Italy. Neurology 2005; 64:1592.</a></li><li><a class="nounderline abstract_t">Maddox RA, Holman RC, Belay ED, et al. Creutzfeldt-Jakob disease among American Indians and Alaska Natives in the United States. Neurology 2006; 66:439.</a></li><li><a class="nounderline abstract_t">Gibbons RV, Holman RC, Belay ED, Schonberger LB. Creutzfeldt-Jakob disease in the United States: 1979-1998. JAMA 2000; 284:2322.</a></li><li><a class="nounderline abstract_t">Collins S, Law MG, Fletcher A, et al. Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study. Lancet 1999; 353:693.</a></li><li><a class="nounderline abstract_t">Ward HJ, Everington D, Cousens SN, et al. Risk factors for sporadic Creutzfeldt-Jakob disease. Ann Neurol 2008; 63:347.</a></li><li><a class="nounderline abstract_t">Ward HJ, Everington D, Croes EA, et al. Sporadic Creutzfeldt-Jakob disease and surgery: a case-control study using community controls. Neurology 2002; 59:543.</a></li><li><a class="nounderline abstract_t">de Pedro-Cuesta J, Mahillo-Fernández I, Rábano A, et al. Nosocomial transmission of sporadic Creutzfeldt-Jakob disease: results from a risk-based assessment of surgical interventions. J Neurol Neurosurg Psychiatry 2011; 82:204.</a></li><li><a class="nounderline abstract_t">Wientjens DP, Davanipour Z, Hofman A, et al. Risk factors for Creutzfeldt-Jakob disease: a reanalysis of case-control studies. Neurology 1996; 46:1287.</a></li><li><a class="nounderline abstract_t">Mead S, Lloyd S, Collinge J. Genetic Factors in Mammalian Prion Diseases. Annu Rev Genet 2019; 53:117.</a></li><li><a class="nounderline abstract_t">Jones E, Hummerich H, Viré E, et al. Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol 2020; 19:840.</a></li><li><a class="nounderline abstract_t">Farmer PM, Kane WC, Hollenberg-Sher J. Incidence of Creutzfeldt-Jakob disease in Brooklyn and Staten Island. N Engl J Med 1978; 298:283.</a></li><li><a class="nounderline abstract_t">Will RG, Matthews WB. Evidence for case-to-case transmission of Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 1982; 45:235.</a></li><li><a class="nounderline abstract_t">Collins S, Boyd A, Fletcher A, et al. Creutzfeldt-Jakob disease cluster in an Australian rural city. Ann Neurol 2002; 52:115.</a></li><li><a class="nounderline abstract_t">Linsell L, Cousens SN, Smith PG, et al. A case-control study of sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of clustering. Neurology 2004; 63:2077.</a></li><li><a class="nounderline abstract_t">Klug GM, Wand H, Boyd A, et al. Enhanced geographically restricted surveillance simulates sporadic Creutzfeldt-Jakob disease cluster. Brain 2009; 132:493.</a></li><li><a class="nounderline abstract_t">Yamakawa Y, Hagiwara K, Nohtomi K, et al. Atypical proteinase K-resistant prion protein (PrPres) observed in an apparently healthy 23-month-old Holstein steer. Jpn J Infect Dis 2003; 56:221.</a></li><li><a class="nounderline abstract_t">Biacabe AG, Laplanche JL, Ryder S, Baron T. Distinct molecular phenotypes in bovine prion diseases. EMBO Rep 2004; 5:110.</a></li><li><a class="nounderline abstract_t">Casalone C, Zanusso G, Acutis P, et al. Identification of a second bovine amyloidotic spongiform encephalopathy: molecular similarities with sporadic Creutzfeldt-Jakob disease. Proc Natl Acad Sci U S A 2004; 101:3065.</a></li><li><a class="nounderline abstract_t">Priola SA, Vorberg I. Identification of possible animal origins of prion disease in human beings. Lancet 2004; 363:2013.</a></li><li><a class="nounderline abstract_t">Brown P, Brandel JP, Sato T, et al. Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg Infect Dis 2012; 18:901.</a></li><li><a class="nounderline abstract_t">Brown P, Preece MA, Will RG. "Friendly fire" in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. Lancet 1992; 340:24.</a></li><li><a class="nounderline abstract_t">Frasier SD. The not-so-good old days: working with pituitary growth hormone in North America, 1956 to 1985. J Pediatr 1997; 131:S1.</a></li><li><a class="nounderline abstract_t">Lewis AM, Yu M, DeArmond SJ, et al. Human growth hormone-related iatrogenic Creutzfeldt-Jakob disease with abnormal imaging. Arch Neurol 2006; 63:288.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts -- Japan, January 1979-May 1996. MMWR Morb Mortal Wkly Rep 1997; 46:1066.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Update: Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts--Japan, 1979-2003. MMWR Morb Mortal Wkly Rep 2003; 52:1179.</a></li><li><a class="nounderline abstract_t">Preusser M, Ströbel T, Gelpi E, et al. Alzheimer-type neuropathology in a 28 year old patient with iatrogenic Creutzfeldt-Jakob disease after dural grafting. J Neurol Neurosurg Psychiatry 2006; 77:413.</a></li><li><a class="nounderline abstract_t">Hamaguchi T, Sakai K, Noguchi-Shinohara M, et al. Insight into the frequent occurrence of dura mater graft-associated Creutzfeldt-Jakob disease in Japan. J Neurol Neurosurg Psychiatry 2013; 84:1171.</a></li><li><a class="nounderline abstract_t">Defebvre L, Destée A, Caron J, et al. Creutzfeldt-Jakob disease after an embolization of intercostal arteries with cadaveric dura mater suggesting a systemic transmission of the prion agent. Neurology 1997; 48:1470.</a></li><li><a class="nounderline abstract_t">Allan B, Tuft S. Transmission of Creutzfeldt-Jakob disease in corneal grafts. BMJ 1997; 315:1553.</a></li><li><a class="nounderline abstract_t">Heckmann JG, Lang CJ, Petruch F, et al. Transmission of Creutzfeldt-Jakob disease via a corneal transplant. J Neurol Neurosurg Psychiatry 1997; 63:388.</a></li><li><a class="nounderline abstract_t">Johnson RT, Gibbs CJ Jr. Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N Engl J Med 1998; 339:1994.</a></li><li><a class="nounderline abstract_t">Brown P, Brandel JP, Preece M, Sato T. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology 2006; 67:389.</a></li><li><a class="nounderline abstract_t">Huillard d'Aignaux J, Costagliola D, Maccario J, et al. Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France. Neurology 1999; 53:1197.</a></li><li><a class="nounderline abstract_t">Heath CA, Barker RA, Esmonde TF, et al. Dura mater-associated Creutzfeldt-Jakob disease: experience from surveillance in the UK. J Neurol Neurosurg Psychiatry 2006; 77:880.</a></li><li><a class="nounderline abstract_t">Furtner M, Gelpi E, Kiechl S, et al. Iatrogenic Creutzfeldt-Jakob disease 22 years after human growth hormone therapy: clinical and radiological features. J Neurol Neurosurg Psychiatry 2008; 79:229.</a></li><li><a class="nounderline abstract_t">Swerdlow AJ, Higgins CD, Adlard P, et al. Creutzfeldt-Jakob disease in United Kingdom patients treated with human pituitary growth hormone. Neurology 2003; 61:783.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Update: Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts--Japan, 1978-2008. MMWR Morb Mortal Wkly Rep 2008; 57:1152.</a></li><li><a class="nounderline abstract_t">Ricketts MN, Cashman NR, Stratton EE, ElSaadany S. Is Creutzfeldt-Jakob disease transmitted in blood? Emerg Infect Dis 1997; 3:155.</a></li><li><a class="nounderline abstract_t">Brown P. Can Creutzfeldt-Jakob disease be transmitted by transfusion? Curr Opin Hematol 1995; 2:472.</a></li><li><a class="nounderline abstract_t">Dorsey K, Zou S, Schonberger LB, et al. Lack of evidence of transfusion transmission of Creutzfeldt-Jakob disease in a US surveillance study. Transfusion 2009; 49:977.</a></li><li><a class="nounderline abstract_t">Patry D, Curry B, Easton D, et al. Creutzfeldt-Jakob disease (CJD) after blood product transfusion from a donor with CJD. Neurology 1998; 50:1872.</a></li><li><a class="nounderline abstract_t">Hillier CE, Salmon RL. Is there evidence for exogenous risk factors in the aetiology and spread of Creutzfeldt-Jakob disease? QJM 2000; 93:617.</a></li><li><a class="nounderline abstract_t">van Duijn CM, Delasnerie-Lauprêtre N, Masullo C, et al. Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. European Union (EU) Collaborative Study Group of Creutzfeldt-Jakob disease (CJD). Lancet 1998; 351:1081.</a></li><li><a class="nounderline abstract_t">Harries-Jones R, Knight R, Will RG, et al. Creutzfeldt-Jakob disease in England and Wales, 1980-1984: a case-control study of potential risk factors. J Neurol Neurosurg Psychiatry 1988; 51:1113.</a></li><li><a class="nounderline abstract_t">Ena J. Prions: who should worry about them? Arch Med Res 2005; 36:622.</a></li><li><a class="nounderline abstract_t">Taylor DM. Preventing accidental transmission of human transmissible spongifom encephalopathies. Br Med Bull 2003; 66:293.</a></li><li><a class="nounderline abstract_t">Blättler T. Implications of prion diseases for neurosurgery. Neurosurg Rev 2002; 25:195.</a></li><li><a class="nounderline abstract_t">Rutala WA, Weber DJ, Society for Healthcare Epidemiology of America. Guideline for disinfection and sterilization of prion-contaminated medical instruments. Infect Control Hosp Epidemiol 2010; 31:107.</a></li><li><a class="nounderline abstract_t">Haywood AM. Transmissible spongiform encephalopathies. N Engl J Med 1997; 337:1821.</a></li><li><a class="nounderline abstract_t">Krasnianski A, Bohling GT, Heinemann U, et al. Neuropsychological Symptoms in Sporadic Creutzfeldt-Jakob Disease Patients in Germany. J Alzheimers Dis 2017; 59:329.</a></li><li><a class="nounderline abstract_t">Rabinovici GD, Wang PN, Levin J, et al. First symptom in sporadic Creutzfeldt-Jakob disease. Neurology 2006; 66:286.</a></li><li><a class="nounderline abstract_t">Krasnianski A, Bohling GT, Harden M, Zerr I. Psychiatric symptoms in patients with sporadic Creutzfeldt-Jakob disease in Germany. J Clin Psychiatry 2015; 76:1209.</a></li><li><a class="nounderline abstract_t">Meissner B, Körtner K, Bartl M, et al. Sporadic Creutzfeldt-Jakob disease: magnetic resonance imaging and clinical findings. Neurology 2004; 63:450.</a></li><li><a class="nounderline abstract_t">Landolt HP, Glatzel M, Blättler T, et al. Sleep-wake disturbances in sporadic Creutzfeldt-Jakob disease. Neurology 2006; 66:1418.</a></li><li><a class="nounderline abstract_t">Thompson A, MacKay A, Rudge P, et al. Behavioral and psychiatric symptoms in prion disease. Am J Psychiatry 2014; 171:265.</a></li><li><a class="nounderline abstract_t">Noguchi-Shinohara M, Hamaguchi T, Kitamoto T, et al. Clinical features and diagnosis of dura mater graft associated Creutzfeldt Jakob disease. Neurology 2007; 69:360.</a></li><li><a class="nounderline abstract_t">Will RG. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br Med Bull 2003; 66:255.</a></li><li><a class="nounderline abstract_t">Boesenberg C, Schulz-Schaeffer WJ, Meissner B, et al. Clinical course in young patients with sporadic Creutzfeldt-Jakob disease. Ann Neurol 2005; 58:533.</a></li><li><a class="nounderline abstract_t">Appleby BS, Appleby KK, Crain BJ, et al. Characteristics of established and proposed sporadic Creutzfeldt-Jakob disease variants. Arch Neurol 2009; 66:208.</a></li><li><a class="nounderline abstract_t">Appleby BS, Appleby KK, Rabins PV. Does the presentation of Creutzfeldt-Jakob disease vary by age or presumed etiology? A meta-analysis of the past 10 years. J Neuropsychiatry Clin Neurosci 2007; 19:428.</a></li><li><a class="nounderline abstract_t">Sakai K, Hamaguchi T, Noguchi-Shinohara M, et al. Graft-related disease progression in dura mater graft-associated Creutzfeldt-Jakob disease: a cross-sectional study. BMJ Open 2013; 3:e003400.</a></li><li class="breakAll">Kirschbaum WR. Jakob-Creutzfeldt disease, Elsevier, New York 1968.</li><li><a class="nounderline abstract_t">Parchi P, Castellani R, Capellari S, et al. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 1996; 39:767.</a></li><li><a class="nounderline abstract_t">Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999; 46:224.</a></li><li><a class="nounderline abstract_t">Lewis V, Hill AF, Klug GM, et al. Australian sporadic CJD analysis supports endogenous determinants of molecular-clinical profiles. Neurology 2005; 65:113.</a></li><li><a class="nounderline abstract_t">Collins SJ, Sanchez-Juan P, Masters CL, et al. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain 2006; 129:2278.</a></li><li><a class="nounderline abstract_t">Cooper SA, Murray KL, Heath CA, et al. Sporadic Creutzfeldt-Jakob disease with cerebellar ataxia at onset in the UK. J Neurol Neurosurg Psychiatry 2006; 77:1273.</a></li><li><a class="nounderline abstract_t">Krasnianski A, Schulz-Schaeffer WJ, Kallenberg K, et al. Clinical findings and diagnostic tests in the MV2 subtype of sporadic CJD. Brain 2006; 129:2288.</a></li><li><a class="nounderline abstract_t">Castellani RJ, Colucci M, Xie Z, et al. Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease. Neurology 2004; 63:436.</a></li><li><a class="nounderline abstract_t">Sanchez-Juan P, Green A, Ladogana A, et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2006; 67:637.</a></li><li><a class="nounderline abstract_t">Krasnianski A, Meissner B, Schulz-Schaeffer W, et al. Clinical features and diagnosis of the MM2 cortical subtype of sporadic Creutzfeldt-Jakob disease. Arch Neurol 2006; 63:876.</a></li><li><a class="nounderline abstract_t">Parchi P, Capellari S, Chin S, et al. A subtype of sporadic prion disease mimicking fatal familial insomnia. Neurology 1999; 52:1757.</a></li><li><a class="nounderline abstract_t">Nozaki I, Hamaguchi T, Noguchi-Shinohara M, et al. The MM2-cortical form of sporadic Creutzfeldt-Jakob disease presenting with visual disturbance. Neurology 2006; 67:531.</a></li><li><a class="nounderline abstract_t">Meissner B, Westner IM, Kallenberg K, et al. Sporadic Creutzfeldt-Jakob disease: clinical and diagnostic characteristics of the rare VV1 type. Neurology 2005; 65:1544.</a></li><li><a class="nounderline abstract_t">Rhoads DD, Wrona A, Foutz A, et al. Diagnosis of prion diseases by RT-QuIC results in improved surveillance. Neurology 2020; 95:e1017.</a></li><li><a class="nounderline abstract_t">Collinge J, Sidle KC, Meads J, et al. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature 1996; 383:685.</a></li><li><a class="nounderline abstract_t">Wadsworth JD, Jackson GS, Hill AF, Collinge J. Molecular biology of prion propagation. Curr Opin Genet Dev 1999; 9:338.</a></li><li><a class="nounderline abstract_t">Hill AF, Joiner S, Wadsworth JD, et al. Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain 2003; 126:1333.</a></li><li><a class="nounderline abstract_t">Head MW, Bunn TJ, Bishop MT, et al. Prion protein heterogeneity in sporadic but not variant Creutzfeldt-Jakob disease: UK cases 1991-2002. Ann Neurol 2004; 55:851.</a></li><li><a class="nounderline abstract_t">Xiang W, Windl O, Westner IM, et al. Cerebral gene expression profiles in sporadic Creutzfeldt-Jakob disease. Ann Neurol 2005; 58:242.</a></li><li><a class="nounderline abstract_t">Schoch G, Seeger H, Bogousslavsky J, et al. Analysis of prion strains by PrPSc profiling in sporadic Creutzfeldt-Jakob disease. PLoS Med 2006; 3:e14.</a></li><li><a class="nounderline abstract_t">Giaccone G, Di Fede G, Mangieri M, et al. A novel phenotype of sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2007; 78:1379.</a></li><li><a class="nounderline abstract_t">Head MW, Ironside JW. Sporadic Creutzfeldt-Jakob disease: discrete subtypes or a spectrum of disease? Brain 2009; 132:2627.</a></li><li><a class="nounderline abstract_t">Cali I, Castellani R, Alshekhlee A, et al. Co-existence of scrapie prion protein types 1 and 2 in sporadic Creutzfeldt-Jakob disease: its effect on the phenotype and prion-type characteristics. Brain 2009; 132:2643.</a></li><li><a class="nounderline abstract_t">Cali I, Puoti G, Smucny J, et al. Co-existence of PrPD types 1 and 2 in sporadic Creutzfeldt-Jakob disease of the VV subgroup: phenotypic and prion protein characteristics. Sci Rep 2020; 10:1503.</a></li><li><a class="nounderline abstract_t">Macfarlane RG, Wroe SJ, Collinge J, et al. Neuroimaging findings in human prion disease. J Neurol Neurosurg Psychiatry 2007; 78:664.</a></li><li><a class="nounderline abstract_t">Collie DA, Sellar RJ, Zeidler M, et al. MRI of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol. Clin Radiol 2001; 56:726.</a></li><li><a class="nounderline abstract_t">Schröter A, Zerr I, Henkel K, et al. Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. Arch Neurol 2000; 57:1751.</a></li><li><a class="nounderline abstract_t">de Priester JA, Jansen GH, de Kruijk JR, Wilmink JT. New MRI findings in Creutzfeldt-Jakob disease: high signal in the globus pallidus on T1-weighted images. Neuroradiology 1999; 41:265.</a></li><li><a class="nounderline abstract_t">Zeidler M, Sellar RJ, Collie DA, et al. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet 2000; 355:1412.</a></li><li><a class="nounderline abstract_t">Finkenstaedt M, Szudra A, Zerr I, et al. MR imaging of Creutzfeldt-Jakob disease. Radiology 1996; 199:793.</a></li><li><a class="nounderline abstract_t">Shiga Y, Miyazawa K, Sato S, et al. Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease. Neurology 2004; 63:443.</a></li><li><a class="nounderline abstract_t">Young GS, Geschwind MD, Fischbein NJ, et al. Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis. AJNR Am J Neuroradiol 2005; 26:1551.</a></li><li><a class="nounderline abstract_t">Ukisu R, Kushihashi T, Kitanosono T, et al. Serial diffusion-weighted MRI of Creutzfeldt-Jakob disease. AJR Am J Roentgenol 2005; 184:560.</a></li><li><a class="nounderline abstract_t">Tschampa HJ, Kallenberg K, Kretzschmar HA, et al. Pattern of cortical changes in sporadic Creutzfeldt-Jakob disease. AJNR Am J Neuroradiol 2007; 28:1114.</a></li><li><a class="nounderline abstract_t">Wada R, Kucharczyk W. Prion infections of the brain. Neuroimaging Clin N Am 2008; 18:183.</a></li><li><a class="nounderline abstract_t">Eisenmenger L, Porter MC, Carswell CJ, et al. Evolution of Diffusion-Weighted Magnetic Resonance Imaging Signal Abnormality in Sporadic Creutzfeldt-Jakob Disease, With Histopathological Correlation. JAMA Neurol 2016; 73:76.</a></li><li><a class="nounderline abstract_t">Ukisu R, Kushihashi T, Tanaka E, et al. Diffusion-weighted MR imaging of early-stage Creutzfeldt-Jakob disease: typical and atypical manifestations. Radiographics 2006; 26 Suppl 1:S191.</a></li><li><a class="nounderline abstract_t">Manners DN, Parchi P, Tonon C, et al. Pathologic correlates of diffusion MRI changes in Creutzfeldt-Jakob disease. Neurology 2009; 72:1425.</a></li><li><a class="nounderline abstract_t">Bavis J, Reynolds P, Tegeler C, Clark P. Asymmetric neuroimaging in Creutzfeldt-Jakob disease: a ruse. J Neuroimaging 2003; 13:376.</a></li><li><a class="nounderline abstract_t">Sibon I, Foubert A, Menegon P, et al. Creutzfeldt-Jakob disease mimicking radiologic posterior reversible leukoencephalopathy. Neurology 2005; 65:329.</a></li><li><a class="nounderline abstract_t">Meissner B, Kallenberg K, Sanchez-Juan P, et al. MRI lesion profiles in sporadic Creutzfeldt-Jakob disease. Neurology 2009; 72:1994.</a></li><li><a class="nounderline abstract_t">Hamaguchi T, Kitamoto T, Sato T, et al. Clinical diagnosis of MM2-type sporadic Creutzfeldt-Jakob disease. Neurology 2005; 64:643.</a></li><li><a class="nounderline abstract_t">Bizzi A, Pascuzzo R, Blevins J, et al. Subtype Diagnosis of Sporadic Creutzfeldt-Jakob Disease with Diffusion Magnetic Resonance Imaging. Ann Neurol 2021; 89:560.</a></li><li><a class="nounderline abstract_t">Cohen OS, Hoffmann C, Lee H, et al. MRI detection of the cerebellar syndrome in Creutzfeldt-Jakob disease. Cerebellum 2009; 8:373.</a></li><li><a class="nounderline abstract_t">Poon MA, Stuckey S, Storey E. MRI evidence of cerebellar and hippocampal involvement in Creutzfeldt-Jakob disease. Neuroradiology 2001; 43:746.</a></li><li><a class="nounderline abstract_t">Fragoso DC, Gonçalves Filho AL, Pacheco FT, et al. Imaging of Creutzfeldt-Jakob Disease: Imaging Patterns and Their Differential Diagnosis. Radiographics 2017; 37:234.</a></li><li><a class="nounderline abstract_t">Demaerel P, Heiner L, Robberecht W, et al. Diffusion-weighted MRI in sporadic Creutzfeldt-Jakob disease. Neurology 1999; 52:205.</a></li><li><a class="nounderline abstract_t">Kallenberg K, Schulz-Schaeffer WJ, Jastrow U, et al. Creutzfeldt-Jakob disease: comparative analysis of MR imaging sequences. AJNR Am J Neuroradiol 2006; 27:1459.</a></li><li><a class="nounderline abstract_t">Lee H, Rosenmann H, Chapman J, et al. Thalamo-striatal diffusion reductions precede disease onset in prion mutation carriers. Brain 2009; 132:2680.</a></li><li><a class="nounderline abstract_t">Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 2009; 132:2659.</a></li><li><a class="nounderline abstract_t">Vitali P, Maccagnano E, Caverzasi E, et al. Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. Neurology 2011; 76:1711.</a></li><li><a class="nounderline abstract_t">Zeidler M, Green A. Advances in diagnosing Creutzfeldt-Jakob disease with MRI and CSF 14-3-3 protein analysis. Neurology 2004; 63:410.</a></li><li><a class="nounderline abstract_t">Bizzi A, Pascuzzo R, Blevins J, et al. Evaluation of a New Criterion for Detecting Prion Disease With Diffusion Magnetic Resonance Imaging. JAMA Neurol 2020; 77:1141.</a></li><li><a class="nounderline abstract_t">Tschampa HJ, Kallenberg K, Urbach H, et al. MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement. Brain 2005; 128:2026.</a></li><li><a class="nounderline abstract_t">Murata T, Shiga Y, Higano S, et al. Conspicuity and evolution of lesions in Creutzfeldt-Jakob disease at diffusion-weighted imaging. AJNR Am J Neuroradiol 2002; 23:1164.</a></li><li><a class="nounderline abstract_t">Caverzasi E, Mandelli ML, DeArmond SJ, et al. White matter involvement in sporadic Creutzfeldt-Jakob disease. Brain 2014; 137:3339.</a></li><li><a class="nounderline abstract_t">Caobelli F, Cobelli M, Pizzocaro C, et al. The role of neuroimaging in evaluating patients affected by Creutzfeldt-Jakob disease: a systematic review of the literature. J Neuroimaging 2015; 25:2.</a></li><li><a class="nounderline abstract_t">Schwaninger M, Winter R, Hacke W, et al. Magnetic resonance imaging in Creutzfeldt-Jakob disease: evidence of focal involvement of the cortex. J Neurol Neurosurg Psychiatry 1997; 63:408.</a></li><li><a class="nounderline abstract_t">Hayashi R, Hanyu N, Kuwabara T, Moriyama S. Serial computed tomographic and electroencephalographic studies in Creutzfeldt-Jakob disease. Acta Neurol Scand 1992; 85:161.</a></li><li><a class="nounderline abstract_t">Itoh Y, Amano T, Shimizu T, et al. Single-photon emission computed tomography image of benzodiazepine receptors in a patient with Creutzfeldt-Jakob disease. Intern Med 1998; 37:896.</a></li><li><a class="nounderline abstract_t">Villemagne VL, McLean CA, Reardon K, et al. 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2009; 80:998.</a></li><li><a class="nounderline abstract_t">Lodi R, Parchi P, Tonon C, et al. Magnetic resonance diagnostic markers in clinically sporadic prion disease: a combined brain magnetic resonance imaging and spectroscopy study. Brain 2009; 132:2669.</a></li><li><a class="nounderline abstract_t">Mente KP, O'Donnell JK, Jones SE, et al. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Correlation of Histopathology and MRI in Prion Disease. Alzheimer Dis Assoc Disord 2017; 31:1.</a></li><li><a class="nounderline abstract_t">Renard D, Castelnovo G, Collombier L, et al. FDG-PET in Creutzfeldt-Jakob disease: Analysis of clinical-PET correlation. Prion 2017; 11:440.</a></li><li><a class="nounderline abstract_t">Matías-Guiu JA, Guerrero-Márquez C, Cabrera-Martín MN, et al. Amyloid- and FDG-PET in sporadic Creutzfeldt-Jakob disease: Correlation with pathological prion protein in neuropathology. Prion 2017; 11:205.</a></li><li><a class="nounderline abstract_t">Day GS, Gordon BA, Perrin RJ, et al. In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology 2018; 90:e896.</a></li><li><a class="nounderline abstract_t">Carrasco García de León S, Cabello JP, Ortiz R, Vaamonde J. Parkinsonism Associated with Pathological 123I-FP-CIT SPECT (DaTSCAN) Results as the Initial Manifestation of Sporadic Creutzfeldt-Jakob Disease. Case Rep Neurol Med 2018; 2018:5157275.</a></li><li><a class="nounderline abstract_t">Steinhoff BJ, Räcker S, Herrendorf G, et al. Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Arch Neurol 1996; 53:162.</a></li><li><a class="nounderline abstract_t">Steinhoff BJ, Zerr I, Glatting M, et al. Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease. Ann Neurol 2004; 56:702.</a></li><li><a class="nounderline abstract_t">Brown P, Gibbs CJ Jr, Rodgers-Johnson P, et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 1994; 35:513.</a></li><li><a class="nounderline abstract_t">Bortone E, Bettoni L, Giorgi C, et al. Reliability of EEG in the diagnosis of Creutzfeldt-Jakob disease. Electroencephalogr Clin Neurophysiol 1994; 90:323.</a></li><li><a class="nounderline abstract_t">Lee RG, Blair RD. Evolution of EEG and visual evoked response changes in Jakob-Creutzfeldt disease. Electroencephalogr Clin Neurophysiol 1973; 35:133.</a></li><li><a class="nounderline abstract_t">Zerr I, Schulz-Schaeffer WJ, Giese A, et al. Current clinical diagnosis in Creutzfeldt-Jakob disease: identification of uncommon variants. Ann Neurol 2000; 48:323.</a></li><li><a class="nounderline abstract_t">Goto K, Umezaki H, Suetsugu M. Electroencephalographic and clinicopathological studies on Creutzfeldt-Jakob syndrome. J Neurol Neurosurg Psychiatry 1976; 39:931.</a></li><li><a class="nounderline abstract_t">NELSON JR, LEFFMAN H. The human diffusely projecting system. Evoked potentials and interactions. Arch Neurol 1963; 8:544.</a></li><li><a class="nounderline abstract_t">Green AJE, Zanusso G. Prion protein amplification techniques. Handb Clin Neurol 2018; 153:357.</a></li><li><a class="nounderline abstract_t">McGuire LI, Peden AH, Orrú CD, et al. Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease. Ann Neurol 2012; 72:278.</a></li><li><a class="nounderline abstract_t">Foutz A, Appleby BS, Hamlin C, et al. Diagnostic and prognostic value of human prion detection in cerebrospinal fluid. Ann Neurol 2017; 81:79.</a></li><li><a class="nounderline abstract_t">Orrú CD, Bongianni M, Tonoli G, et al. A test for Creutzfeldt-Jakob disease using nasal brushings. N Engl J Med 2014; 371:519.</a></li><li><a class="nounderline abstract_t">Bongianni M, Orrù C, Groveman BR, et al. Diagnosis of Human Prion Disease Using Real-Time Quaking-Induced Conversion Testing of Olfactory Mucosa and Cerebrospinal Fluid Samples. JAMA Neurol 2017; 74:155.</a></li><li><a class="nounderline abstract_t">Hsich G, Kenney K, Gibbs CJ, et al. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 1996; 335:924.</a></li><li><a class="nounderline abstract_t">Zerr I, Bodemer M, Gefeller O, et al. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol 1998; 43:32.</a></li><li><a class="nounderline abstract_t">Kenney K, Hsich G, Brechtel C, Gibbs CJ. The cerebrospinal fluid 14-3-3- assay's diagnostic utility among clinically suspected Creutzfeldt-Jakob disease patients: the NIH experience. Neurol 2002; 58(Suppl 3):A250 (abstract).</a></li><li><a class="nounderline abstract_t">Geschwind MD, Martindale J, Miller D, et al. Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch Neurol 2003; 60:813.</a></li><li><a class="nounderline abstract_t">Chohan G, Pennington C, Mackenzie JM, et al. The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review. J Neurol Neurosurg Psychiatry 2010; 81:1243.</a></li><li><a class="nounderline abstract_t">Muayqil T, Gronseth G, Camicioli R. Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2012; 79:1499.</a></li><li><a class="nounderline abstract_t">Chapman T, McKeel DW Jr, Morris JC. Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000; 55:1396.</a></li><li><a class="nounderline abstract_t">Satoh J, Kurohara K, Yukitake M, Kuroda Y. The 14-3-3 protein detectable in the cerebrospinal fluid of patients with prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture. Eur Neurol 1999; 41:216.</a></li><li><a class="nounderline abstract_t">Stoeck K, Sanchez-Juan P, Gawinecka J, et al. Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain 2012; 135:3051.</a></li><li><a class="nounderline abstract_t">Van Everbroeck BR, Boons J, Cras P. 14-3-3 {gamma}-isoform detection distinguishes sporadic Creutzfeldt-Jakob disease from other dementias. J Neurol Neurosurg Psychiatry 2005; 76:100.</a></li><li><a class="nounderline abstract_t">Zanusso G, Fiorini M, Farinazzo A, et al. Phosphorylated 14-3-3zeta protein in the CSF of neuroleptic-treated patients. Neurology 2005; 64:1618.</a></li><li><a class="nounderline abstract_t">Hamlin C, Puoti G, Berri S, et al. A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease. Neurology 2012; 79:547.</a></li><li><a class="nounderline abstract_t">Otto M, Wiltfang J, Cepek L, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002; 58:192.</a></li><li><a class="nounderline abstract_t">Forner SA, Takada LT, Bettcher BM, et al. Comparing CSF biomarkers and brain MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease. Neurol Clin Pract 2015; 5:116.</a></li><li><a class="nounderline abstract_t">Skillbäck T, Rosén C, Asztely F, et al. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. JAMA Neurol 2014; 71:476.</a></li><li><a class="nounderline abstract_t">Llorens F, Rübsamen N, Hermann P, et al. A prognostic model for overall survival in sporadic Creutzfeldt-Jakob disease. Alzheimers Dement 2020; 16:1438.</a></li><li><a class="nounderline abstract_t">Zerr I, Villar-Piqué A, Hermann P, et al. Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease. Alzheimers Res Ther 2021; 13:86.</a></li><li><a class="nounderline abstract_t">Zerr I, Bodemer M, Otto M, et al. Diagnosis of Creutzfeldt-Jakob disease by two-dimensional gel electrophoresis of cerebrospinal fluid. Lancet 1996; 348:846.</a></li><li><a class="nounderline abstract_t">Le Pera M, Urso E, Sprovieri T, et al. Contribution of cerebrospinal fluid thymosin β4 levels to the clinical differentiation of Creutzfeldt-Jakob disease. Arch Neurol 2012; 69:868.</a></li><li><a class="nounderline abstract_t">Coulthart MB, Jansen GH, Cashman NR. Interpretation of cerebrospinal fluid protein tests in the diagnosis of sporadic Creutzfeldt-Jakob disease: an evidence-based approach. CMAJ 2014; 186:E333.</a></li><li><a class="nounderline abstract_t">Fratini F, Principe S, Puopolo M, et al. Increased levels of acute-phase inflammatory proteins in plasma of patients with sporadic CJD. Neurology 2012; 79:1012.</a></li><li><a class="nounderline abstract_t">Hermann P, Appleby B, Brandel JP, et al. Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol 2021; 20:235.</a></li><li><a class="nounderline abstract_t">Shaked GM, Shaked Y, Kariv-Inbal Z, et al. A protease-resistant prion protein isoform is present in urine of animals and humans affected with prion diseases. J Biol Chem 2001; 276:31479.</a></li><li><a class="nounderline abstract_t">Head MW, Kouverianou E, Taylor L, et al. Evaluation of urinary PrPSc as a diagnostic test for sporadic, variant, and familial CJD. Neurology 2005; 64:1794.</a></li><li><a class="nounderline abstract_t">Zanusso G, Ferrari S, Cardone F, et al. Detection of pathologic prion protein in the olfactory epithelium in sporadic Creutzfeldt-Jakob disease. N Engl J Med 2003; 348:711.</a></li><li><a class="nounderline abstract_t">Glatzel M, Abela E, Maissen M, Aguzzi A. Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. N Engl J Med 2003; 349:1812.</a></li><li><a class="nounderline abstract_t">Favereaux A, Quadrio I, Vital C, et al. Pathologic prion protein spreading in the peripheral nervous system of a patient with sporadic Creutzfeldt-Jakob disease. Arch Neurol 2004; 61:747.</a></li><li><a class="nounderline abstract_t">Quadrio I, Ugnon-Café S, Dupin M, et al. Rapid diagnosis of human prion disease using streptomycin with tonsil and brain tissues. Lab Invest 2009; 89:406.</a></li><li><a class="nounderline abstract_t">Orrú CD, Yuan J, Appleby BS, et al. Prion seeding activity and infectivity in skin samples from patients with sporadic Creutzfeldt-Jakob disease. Sci Transl Med 2017; 9.</a></li><li><a class="nounderline abstract_t">Orrù CD, Soldau K, Cordano C, et al. Prion Seeds Distribute throughout the Eyes of Sporadic Creutzfeldt-Jakob Disease Patients. mBio 2018; 9.</a></li><li><a class="nounderline abstract_t">Pan T, Sethi J, Nelsen C, et al. Detection of misfolded prion protein in blood with conformationally sensitive peptides. Transfusion 2007; 47:1418.</a></li><li><a class="nounderline abstract_t">Cathala F, Brown P, Castaigne P, Gajdusek DC. [Creutzfeldt-Jacob disease in continental France. Retrospective study from 1968 to 1977]. Rev Neurol (Paris) 1979; 135:439.</a></li><li><a class="nounderline abstract_t">Kretzschmar HA, Ironside JW, DeArmond SJ, Tateishi J. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol 1996; 53:913.</a></li><li><a class="nounderline abstract_t">Brandel JP, Delasnerie-Lauprêtre N, Laplanche JL, et al. Diagnosis of Creutzfeldt-Jakob disease: effect of clinical criteria on incidence estimates. Neurology 2000; 54:1095.</a></li><li class="breakAll">CDC's Diagnostic Criteria for Creutzfeldt-Jakob Disease (CJD), 2010 http://www.cdc.gov/ncidod/dvrd/cjd/diagnostic_criteria.html (Accessed on June 07, 2011).</li><li><a class="nounderline abstract_t">Appleby BS, Yobs DR. Symptomatic treatment, care, and support of CJD patients. Handb Clin Neurol 2018; 153:399.</a></li><li><a class="nounderline abstract_t">Safar JG, Geschwind MD, Deering C, et al. Diagnosis of human prion disease. Proc Natl Acad Sci U S A 2005; 102:3501.</a></li><li><a class="nounderline abstract_t">Gambetti P, Kong Q, Zou W, et al. Sporadic and familial CJD: classification and characterisation. Br Med Bull 2003; 66:213.</a></li><li><a class="nounderline abstract_t">Heinemann U, Krasnianski A, Meissner B, et al. Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance. Brain 2007; 130:1350.</a></li><li><a class="nounderline abstract_t">Pocchiari M, Puopolo M, Croes EA, et al. Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain 2004; 127:2348.</a></li><li><a class="nounderline abstract_t">Stewart LA, Rydzewska LH, Keogh GF, Knight RS. Systematic review of therapeutic interventions in human prion disease. Neurology 2008; 70:1272.</a></li><li><a class="nounderline abstract_t">Perovic S, Schröder HC, Pergande G, et al. Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126). Exp Neurol 1997; 147:518.</a></li><li><a class="nounderline abstract_t">Müller WE, Romero FJ, Perovic S, et al. Protection of flupirtine on beta-amyloid-induced apoptosis in neuronal cells in vitro: prevention of amyloid-induced glutathione depletion. J Neurochem 1997; 68:2371.</a></li><li><a class="nounderline abstract_t">Korth C, Peters PJ. Emerging pharmacotherapies for Creutzfeldt-Jakob disease. Arch Neurol 2006; 63:497.</a></li><li><a class="nounderline abstract_t">Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. Neurology 2004; 62:714.</a></li><li><a class="nounderline abstract_t">Bone I, Belton L, Walker AS, Darbyshire J. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur J Neurol 2008; 15:458.</a></li><li><a class="nounderline abstract_t">Tsuboi Y, Doh-Ura K, Yamada T. Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases. Neuropathology 2009; 29:632.</a></li><li><a class="nounderline abstract_t">Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A 2001; 98:9836.</a></li><li><a class="nounderline abstract_t">Haïk S, Brandel JP, Salomon D, et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology 2004; 63:2413.</a></li><li><a class="nounderline abstract_t">Collinge J, Gorham M, Hudson F, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol 2009; 8:334.</a></li><li><a class="nounderline abstract_t">Geschwind MD, Kuo AL, Wong KS, et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology 2013; 81:2015.</a></li><li><a class="nounderline abstract_t">Forloni G, Salmona M, Marcon G, Tagliavini F. Tetracyclines and prion infectivity. Infect Disord Drug Targets 2009; 9:23.</a></li><li><a class="nounderline abstract_t">Haïk S, Marcon G, Mallet A, et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014; 13:150.</a></li><li><a class="nounderline abstract_t">Varges D, Manthey H, Heinemann U, et al. Doxycycline in early CJD: a double-blinded randomised phase II and observational study. J Neurol Neurosurg Psychiatry 2017; 88:119.</a></li><li><a class="nounderline abstract_t">Forloni G, Tettamanti M, Lucca U, et al. Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases. Prion 2015; 9:75.</a></li><li><a class="nounderline abstract_t">Minikel EV, Zhao HT, Le J, et al. Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints. Nucleic Acids Res 2020; 48:10615.</a></li><li><a class="nounderline abstract_t">Vallabh SM, Minikel EV, Schreiber SL, Lander ES. Towards a treatment for genetic prion disease: trials and biomarkers. Lancet Neurol 2020; 19:361.</a></li></ol></div><div id="topicVersionRevision">Topic 5084 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22710755" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Sporadic human prion diseases: molecular insights and diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/371520" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15883321" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23965290" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Intensity of human prion disease surveillance predicts observed disease incidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3295589" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The epidemiology of Creutzfeldt-Jakob disease: conclusion of a 15-year investigation in France and review of the world literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7031189" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Creutzfeldt-Jakob disease in an adolescent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9373595" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Creutzfeldt-Jakob disease in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16148290" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Case records of the Massachusetts General Hospital. Case 27-2005. An 80-year-old man with fatigue, unsteady gait, and confusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15883322" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : High incidence of genetic human transmissible spongiform encephalopathies in Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16476950" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Creutzfeldt-Jakob disease among American Indians and Alaska Natives in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11066181" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Creutzfeldt-Jakob disease in the United States: 1979-1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10073510" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18074392" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk factors for sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12196646" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Sporadic Creutzfeldt-Jakob disease and surgery: a case-control study using community controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20547628" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Nosocomial transmission of sporadic Creutzfeldt-Jakob disease: results from a risk-based assessment of surgical interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8628468" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Risk factors for Creutzfeldt-Jakob disease: a reanalysis of case-control studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31537104" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Genetic Factors in Mammalian Prion Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32949544" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/339092" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Incidence of Creutzfeldt-Jakob disease in Brooklyn and Staten Island.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7045290" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Evidence for case-to-case transmission of Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12112059" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Creutzfeldt-Jakob disease cluster in an Australian rural city.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15596753" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A case-control study of sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of clustering.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19042933" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Enhanced geographically restricted surveillance simulates sporadic Creutzfeldt-Jakob disease cluster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14695437" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Atypical proteinase K-resistant prion protein (PrPres) observed in an apparently healthy 23-month-old Holstein steer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14710195" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Distinct molecular phenotypes in bovine prion diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14970340" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Identification of a second bovine amyloidotic spongiform encephalopathy: molecular similarities with sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15207949" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Identification of possible animal origins of prion disease in human beings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22607808" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Iatrogenic Creutzfeldt-Jakob disease, final assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1351607" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : "Friendly fire" in medicine: hormones, homografts, and Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9255217" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The not-so-good old days: working with pituitary growth hormone in North America, 1956 to 1985.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16476821" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Human growth hormone-related iatrogenic Creutzfeldt-Jakob disease with abnormal imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9385874" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts -- Japan, January 1979-May 1996.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14654766" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Update: Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts--Japan, 1979-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16484658" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Alzheimer-type neuropathology in a 28 year old patient with iatrogenic Creutzfeldt-Jakob disease after dural grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23595947" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Insight into the frequent occurrence of dura mater graft-associated Creutzfeldt-Jakob disease in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9153501" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Creutzfeldt-Jakob disease after an embolization of intercostal arteries with cadaveric dura mater suggesting a systemic transmission of the prion agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9437268" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Transmission of Creutzfeldt-Jakob disease in corneal grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9328261" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Transmission of Creutzfeldt-Jakob disease via a corneal transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9869672" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16855204" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Iatrogenic Creutzfeldt-Jakob disease: the waning of an era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10522872" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16627534" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Dura mater-associated Creutzfeldt-Jakob disease: experience from surveillance in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18202218" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Iatrogenic Creutzfeldt-Jakob disease 22 years after human growth hormone therapy: clinical and radiological features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14504321" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Creutzfeldt-Jakob disease in United Kingdom patients treated with human pituitary growth hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18946463" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Update: Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts--Japan, 1978-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9204296" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Is Creutzfeldt-Jakob disease transmitted in blood?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9372038" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Can Creutzfeldt-Jakob disease be transmitted by transfusion?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19170987" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Lack of evidence of transfusion transmission of Creutzfeldt-Jakob disease in a US surveillance study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9633747" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Creutzfeldt-Jakob disease (CJD) after blood product transfusion from a donor with CJD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10984557" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Is there evidence for exogenous risk factors in the aetiology and spread of Creutzfeldt-Jakob disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9660576" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. European Union (EU) Collaborative Study Group of Creutzfeldt-Jakob disease (CJD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3066847" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Creutzfeldt-Jakob disease in England and Wales, 1980-1984: a case-control study of potential risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16216643" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prions: who should worry about them?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14522866" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Preventing accidental transmission of human transmissible spongifom encephalopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12172722" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Implications of prion diseases for neurosurgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20055640" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Guideline for disinfection and sterilization of prion-contaminated medical instruments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9400041" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Transmissible spongiform encephalopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28598840" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Neuropsychological Symptoms in Sporadic Creutzfeldt-Jakob Disease Patients in Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16434680" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : First symptom in sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25938948" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Psychiatric symptoms in patients with sporadic Creutzfeldt-Jakob disease in Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15314808" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Sporadic Creutzfeldt-Jakob disease: magnetic resonance imaging and clinical findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16682677" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Sleep-wake disturbances in sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24585329" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Behavioral and psychiatric symptoms in prion disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17646628" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical features and diagnosis of dura mater graft associated Creutzfeldt Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14522863" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Acquired prion disease: iatrogenic CJD, variant CJD, kuru.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16037975" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Clinical course in young patients with sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19204157" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Characteristics of established and proposed sporadic Creutzfeldt-Jakob disease variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18070846" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Does the presentation of Creutzfeldt-Jakob disease vary by age or presumed etiology? A meta-analysis of the past 10 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23975105" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Graft-related disease progression in dura mater graft-associated Creutzfeldt-Jakob disease: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23975105" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Graft-related disease progression in dura mater graft-associated Creutzfeldt-Jakob disease: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8651649" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10443888" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009895" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Australian sporadic CJD analysis supports endogenous determinants of molecular-clinical profiles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16816392" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16835290" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Sporadic Creutzfeldt-Jakob disease with cerebellar ataxia at onset in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16720682" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Clinical findings and diagnostic tests in the MV2 subtype of sporadic CJD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304573" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16924018" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16769870" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Clinical features and diagnosis of the MM2 cortical subtype of sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10371520" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : A subtype of sporadic prion disease mimicking fatal familial insomnia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16894125" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The MM2-cortical form of sporadic Creutzfeldt-Jakob disease presenting with visual disturbance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16221949" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Sporadic Creutzfeldt-Jakob disease: clinical and diagnostic characteristics of the rare VV1 type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32571851" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Diagnosis of prion diseases by RT-QuIC results in improved surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8878476" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10377292" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Molecular biology of prion propagation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12764055" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Molecular classification of sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15174020" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Prion protein heterogeneity in sporadic but not variant Creutzfeldt-Jakob disease: UK cases 1991-2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16049922" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cerebral gene expression profiles in sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16354106" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Analysis of prion strains by PrPSc profiling in sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18024694" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : A novel phenotype of sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19759201" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Sporadic Creutzfeldt-Jakob disease: discrete subtypes or a spectrum of disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19734292" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Co-existence of scrapie prion protein types 1 and 2 in sporadic Creutzfeldt-Jakob disease: its effect on the phenotype and prion-type characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32001774" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Co-existence of PrPD types 1 and 2 in sporadic Creutzfeldt-Jakob disease of the VV subgroup: phenotypic and prion protein characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17135459" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Neuroimaging findings in human prion disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11585394" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : MRI of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11115241" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10344511" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : New MRI findings in Creutzfeldt-Jakob disease: high signal in the globus pallidus on T1-weighted images.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10791525" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8638007" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : MR imaging of Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304574" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15956529" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15671380" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Serial diffusion-weighted MRI of Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17569970" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Pattern of cortical changes in sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18319162" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Prion infections of the brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26569479" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Evolution of Diffusion-Weighted Magnetic Resonance Imaging Signal Abnormality in Sporadic Creutzfeldt-Jakob Disease, With Histopathological Correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17050516" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Diffusion-weighted MR imaging of early-stage Creutzfeldt-Jakob disease: typical and atypical manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19380702" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Pathologic correlates of diffusion MRI changes in Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14569834" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Asymmetric neuroimaging in Creutzfeldt-Jakob disease: a ruse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16043814" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Creutzfeldt-Jakob disease mimicking radiologic posterior reversible leukoencephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19506221" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : MRI lesion profiles in sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728285" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Clinical diagnosis of MM2-type sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33274461" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Subtype Diagnosis of Sporadic Creutzfeldt-Jakob Disease with Diffusion Magnetic Resonance Imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19408064" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : MRI detection of the cerebellar syndrome in Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11594424" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : MRI evidence of cerebellar and hippocampal involvement in Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28076012" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Imaging of Creutzfeldt-Jakob Disease: Imaging Patterns and Their Differential Diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9921880" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Diffusion-weighted MRI in sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16908558" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Creutzfeldt-Jakob disease: comparative analysis of MR imaging sequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19321460" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Thalamo-striatal diffusion reductions precede disease onset in prion mutation carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19773352" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21471469" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304568" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Advances in diagnosing Creutzfeldt-Jakob disease with MRI and CSF 14-3-3 protein analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32478816" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Evaluation of a New Criterion for Detecting Prion Disease With Diffusion Magnetic Resonance Imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15958503" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12169476" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Conspicuity and evolution of lesions in Creutzfeldt-Jakob disease at diffusion-weighted imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25367029" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : White matter involvement in sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24593302" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : The role of neuroimaging in evaluating patients affected by Creutzfeldt-Jakob disease: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9328267" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Magnetic resonance imaging in Creutzfeldt-Jakob disease: evidence of focal involvement of the cortex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1574996" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Serial computed tomographic and electroencephalographic studies in Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9840717" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Single-photon emission computed tomography image of benzodiazepine receptors in a patient with Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332421" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19755520" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Magnetic resonance diagnostic markers in clinically sporadic prion disease: a combined brain magnetic resonance imaging and spectroscopy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28121634" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Correlation of Histopathology and MRI in Prion Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29099286" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : FDG-PET in Creutzfeldt-Jakob disease: Analysis of clinical-PET correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28509609" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Amyloid- and FDG-PET in sporadic Creutzfeldt-Jakob disease: Correlation with pathological prion protein in neuropathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29438042" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29955403" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Parkinsonism Associated with Pathological 123I-FP-CIT SPECT (DaTSCAN) Results as the Initial Manifestation of Sporadic Creutzfeldt-Jakob Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8639066" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15449324" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8179297" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7514979" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Reliability of EEG in the diagnosis of Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4124605" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Evolution of EEG and visual evoked response changes in Jakob-Creutzfeldt disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10976638" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Current clinical diagnosis in Creutzfeldt-Jakob disease: identification of uncommon variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/794444" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Electroencephalographic and clinicopathological studies on Creutzfeldt-Jakob syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13938046" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : The human diffusely projecting system. Evoked potentials and interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29887145" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Prion protein amplification techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22926858" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27893164" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Diagnostic and prognostic value of human prion detection in cerebrospinal fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25099576" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : A test for Creutzfeldt-Jakob disease using nasal brushings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27942718" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Diagnosis of Human Prion Disease Using Real-Time Quaking-Induced Conversion Testing of Olfactory Mucosa and Cerebrospinal Fluid Samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8782499" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9450766" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : The cerebrospinal fluid 14-3-3- assay's diagnostic utility among clinically suspected Creutzfeldt-Jakob disease patients: the NIH experience</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12810484" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855493" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22993290" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: report of the guideline development subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11087791" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10343153" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : The 14-3-3 protein detectable in the cerebrospinal fluid of patients with prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23012332" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15608004" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : 14-3-3 {gamma}-isoform detection distinguishes sporadic Creutzfeldt-Jakob disease from other dementias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15883327" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Phosphorylated 14-3-3zeta protein in the CSF of neuroleptic-treated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22843257" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11805244" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26137420" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Comparing CSF biomarkers and brain MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24566866" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32614136" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : A prognostic model for overall survival in sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33883011" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8826809" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Diagnosis of Creutzfeldt-Jakob disease by two-dimensional gel electrophoresis of cerebrospinal fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22431836" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Contribution of cerebrospinal fluid thymosinβ4 levels to the clinical differentiation of Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24446456" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Interpretation of cerebrospinal fluid protein tests in the diagnosis of sporadic Creutzfeldt-Jakob disease: an evidence-based approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22855863" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Increased levels of acute-phase inflammatory proteins in plasma of patients with sporadic CJD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33609480" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11423531" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : A protease-resistant prion protein isoform is present in urine of animals and humans affected with prion diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15911815" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Evaluation of urinary PrPSc as a diagnostic test for sporadic, variant, and familial CJD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12594315" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Detection of pathologic prion protein in the olfactory epithelium in sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14602879" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15148153" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Pathologic prion protein spreading in the peripheral nervous system of a patient with sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19188908" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Rapid diagnosis of human prion disease using streptomycin with tonsil and brain tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29167394" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Prion seeding activity and infectivity in skin samples from patients with sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30459197" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Prion Seeds Distribute throughout the Eyes of Sporadic Creutzfeldt-Jakob Disease Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17655586" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Detection of misfolded prion protein in blood with conformationally sensitive peptides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/395612" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : [Creutzfeldt-Jacob disease in continental France. Retrospective study from 1968 to 1977].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8815857" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Diagnostic criteria for sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10720280" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Diagnosis of Creutzfeldt-Jakob disease: effect of clinical criteria on incidence estimates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10720280" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Diagnosis of Creutzfeldt-Jakob disease: effect of clinical criteria on incidence estimates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29887147" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Symptomatic treatment, care, and support of CJD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741275" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Diagnosis of human prion disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14522861" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Sporadic and familial CJD: classification and characterisation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17472986" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15361416" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18391159" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Systematic review of therapeutic interventions in human prion disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9344576" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9166730" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Protection of flupirtine on beta-amyloid-induced apoptosis in neuronal cells in vitro: prevention of amyloid-induced glutathione depletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16606761" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Emerging pharmacotherapies for Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15007119" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18355301" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19788637" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11504948" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15623716" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19278902" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24122181" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19200012" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : Tetracyclines and prion infectivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24411709" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27807198" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : Doxycycline in early CJD: a double-blinded randomised phase II and observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25996399" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32776089" id="rid204" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>205 : Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32199098" id="rid205" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>206 : Towards a treatment for genetic prion disease: trials and biomarkers.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
